Connect public, paid and private patent data with Google Patents Public Datasets

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Download PDF

Info

Publication number
USRE42461E1
USRE42461E1 US12797341 US79734194A USRE42461E US RE42461 E1 USRE42461 E1 US RE42461E1 US 12797341 US12797341 US 12797341 US 79734194 A US79734194 A US 79734194A US RE42461 E USRE42461 E US RE42461E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
ar
formula
ch
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US12797341
Inventor
Stuart B. Rosenblum
Sundeep Dugar
Duane A. Burnett
John W. Clader
Brian A. McKittrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme Corp
Original Assignee
Merck Sharp & Dohme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/55Synthetic design, e.g. reducing the use of auxiliary or protecting groups

Abstract

Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula

or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 are aryl or R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—;
R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7;
R1 and R3 are H or lower alkyl;
q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5;
R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6;
R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic
R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.

Description

The present application is the United States national application corresponding to International Application No. PCT/US94/10099, filed Sep. 14, 1994 and designating the United States, which PCT application is in turn a continuation-in-part of U.S. application Ser. No. 08/257593, filed Jun. 9, 1994, U.S. Pat. No. 5,631,365, which is a continuation-in-part of U.S. application Ser. No. 08/102,440, filed Sep. 21, 1993, abandoned.

BACKGROUND OF THE INVENTION

The present invention rotates to hydroxy-substituted azetidinones useful as hypocholesterolemic agents in the treatment prevention of atherosclerosis, and to the combination of a hydroxy-substituted azetidinone of this invention and a cholesterol bioxynthesis inhibitor for the treatment and prevention of atherosclerosis. The invention also relates to a process for preparing hydroxy-substituted azetidinones.

Atherosclerotic coronary heart disease (CHD) represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigar smoke and serum cholesterol. A total cholesterol level in excess of 225-250 mg/dl is associated with significant elevation of risk of CHD.

Cholesteryl esters are a major component of atherosclerotic lesions and the major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters is also a key step in the intestinal absorption of dietary cholesterol. Thus, inhibition of cholesteryl ester formation and reduction of serum cholesterol is likely to inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesterol esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.

A few azetidinones have been reported as being useful lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls. U.S. Pat. No. 4,983,597 discloses N-sulfonyl-2-azetichnones as anticholesterolemic agents and Ram, et al., in Indian J. Chem., Sect. B. 29B, 12 (1990), p. 1134-7, disclose ethyl 4-(2-oxoazetidin-4-yl)phenoxy-alkanoates as hypolipidemic agents. European Patent Publication 264,231 discloses 1-substituted-4-phenyl-3-(2-oxo-alkylidene)-2-azetidinones as blood platelet aggregation inhibitors. European Patent 199,630 and European Patent Application 337,549 disclose elastase inhibitory substituted azetidinones said to be useful treating inflammatory conditions resulting in tissue destruction which are associated with various disease states, e.g. atherosclerosis.

WO93/102048, published Feb. 4, 1993, discloses substituted β-lactams useful as hypocholesterolemic agents.

The regulation of whole-body cholesterol homeostasis in humans and animals involves the regulation of dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. The liver is the major organ responsible for cholesterol biosynthesis and catabolism and for this reason, it is a prime determinant of plasma cholesterol levels. The liver is the site of synthesis and secretion of very low density lipoproteins (VLDL) which are subsequently metabolized to low density lipoproteins (LDL) in the circulation. LDL are the predominant cholesterol-carrying lipoproteins in the plasma and an increase in their concentration is correlated with increased atherosclerosis.

When intestinal cholesterol absorption is reduced, by whatever means, less cholesterol is delivered to the liver. The consequence of this action is decreased hepatic lipoprotein (VLDL), production and an increase in the hepatic clearance of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in plasma cholesterol levels.

The inhibition of cholesterol biosynthesis by 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (EC1.1.1.34) inhibitors has been shown to be an effective way to reduce plasma cholesterol (Witzum, Circulation, 80, 5 (1989), p. 1101-1114) and reduce atherosclerosis. Combination therapy of an HMG CoA reductase inhibitor and a bile acid sequestrant has been demonstrated to be more effective in human hyperlipidemic patients than either agent in monotherapy (Illingworth, Drugs, 36 (Suppl. 3) (1988), p. 63-71).

SUMMARY OF THE INVENTION

Novel hypocholesterolemic compounds of the present invention are represented by the formula I


or a pharmaceutically acceptable salt thereof, wherein:

Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;

Ar3 is aryl or R5-substituted aryl;

X, Y and Z are independently selected from the group consisting of —CH2—, —CH(lower alkyl)— and —C(dilower alkyl)—;

R and R2 are independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7;

R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;

q is 0 or 1; r is 0 or 1; m, n and p are independently 0, 1, 2, 3 or 4; provided that at least One of q and r is 1, and the sum of m, n, p, q are r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4, or 5;

R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, —OR6, —O(CO)R6,R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6, —CH═CH—COOR6, —CF3, —CN, —NO2 and halogen;

R5 is 1-5 substituents independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6;

R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and

R9 is lower alkyl, aryl or aryl-substituted lower alkyl.

R4 is preferably 1-3 independently selected substituents, and R5 is preferably 1-3 independently selected substituents. Preferred are compounds of formula I wherein Ar1 is phenyl or R4-substituted phenyl, especially (4-R4)-substituted phenyl, Ar2 is preferably phenyl or R4-substituted phenyl, especially (4-R4)-substituted phenyl. Ar3 is preferably R5-substituted phenyl, especially (4-R5)-substituted phenyl. When Ar1 is (4-R4)-substituted phenyl, R4 is preferably a halogen. When Ar2 and Ar3 are R4- and R5-substituted phenyl, respectively, R4 is preferably halogen or —OR6 and R5 is preferably —OR6, wherein R6 is lower alkyl or hydrogen. Especially preferred are compounds wherein each of Ar1 and Ar2 is 4-fluorophenyl and Ar3 is 4-hydroxyphenyl or 4-methoxyphenyl.

X, Y and Z are each preferably —CH2—.R1 and R3 are each preferably hydrogen. R and R2 are preferably —OR6 wherein R6 is hydrogen, or a group readily metabolizable to a hydroxyl (such as —O(CO)R6, —O(CO)OR9 and —OR6, especially —O(CO)NR6R7, defined above).

The sum of m, n, p, q and r is preferably 2, 3 or 4, more preferably 3. Preferred are compounds wherein m, n and r are each zero, q is 1 and p is 2. Also preferred are compounds wherein p, q and n are each zero, r is 1 and m is 2 or 3. More preferred are compounds wherein m, n and r are each zero, q is 1, p is 2, Z is —CH2 and R is —OR6OR6, especially when R6 is hydrogen. Also more preferred are compounds wherein p, q and n are each zero, r is 1, m is 2, X is —CH2— and R2 is —OR6, especially when R6 is hydrogen.

Another group of preferred compounds is that wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl and Ar3 is R5-substituted phenyl. Also preferred are compounds wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl, Ar3is R5-substituted phenyl, and the sum of m, n, p, q and r is 2, 3 or 4, more especially 3. More preferred are compounds wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl Ar3 is R5-substituted phenyl, and wherein m, n and r are each zero, q is 1 and p is 2, or wherein p, q and n are each zero, r is 1 and m is 2 or 3.

This invention also relates to a method of lowering the serum cholesterol level in a mammal in need of such treatment comprising administering an effective amount of a compound of formula I. That is, the use of a compound of the present invention as an hypocholesterolemic agent is also claimed.

In still another aspect, the present invention relates to a pharmaceutical composition comprising a serum cholesterol-lowering effective amount of a compound of formula I in a pharmaceutically acceptable carrier.

The present invention also relates to a method of reducing plasma cholesterol levels, and to a method of treating or preventing atherosclerosis, comprising administering to a mammal in need of such treatment an effective amount of a combination of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I and a cholesterol biosynthesis inhibitor. That is, the present invention relates to the use of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I for combined use with a cholesterol biosynthesis inhibitor (and, similarly, use of a cholesterol biosynthesis inhibitor for combined use with a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I) to treat or prevent atherosclerosis or to reduce plasma cholesterol levels.

In yet another aspect, the invention relates to a pharmaceutical composition comprising an effective amount of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I, a cholesterol biosynthesis inhibitor, and a pharmaceutically acceptable carrier. In a final aspect, the invention relates to a kit comprising in one container an effective amount of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I in a pharmaceutically acceptable carrier, and in a separate container, an effective amount of a cholesterol biosynthesis inhibitor in a pharmaceutically acceptable carrier.

In yet another aspect, the invention relates to a process for preparing certain compounds of formula I comprising the steps:

(a) treating with a strong base a lactone of the formula


wherein R′ and R2′ are R and R2, respectively, or are suitably protected hydroxy groups; Ar10 is Ar1, a suitably protected hydroxy substituted aryl or a suitably protected amino-substituted aryl; and the remaining variables are as defined above, provided that in lactone of formula B when n and r are each zero, p is 1-4;

(b) reacting the product of step (a) with an imine of the formula

wherein Ar20 is Ar2, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl; and Ar30 is Ar3, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl;

c) quenching the reaction with an acid;

d) optionally removing the protecting groups from R′, R2′, Ar10, Ar20 and Ar30, when present; and

c) optionally functionalizing hydroxy or amino substituents at R, R2, Ar1, Ar2 and Ar3.

Using the lactones shown above, compounds of formula IA and IB are obtained as follows:


wherein the variables are as defined above; and


wherein the variables are as defined above.

DETAILED DESCRIPTION

As used herein, the term “lower alkyl” means straight or branched alkyl chains of 1 to 6 carbon atoms.

“Aryl” means phenyl, naphthyl, indenyl, tetrahydronaphthyl or indanyl.

“Halogen” refers to fluorine, chlorine, bromine or iodine atoms.

The above statement, wherein R6, R7 and R8 are said to be independently selected from a group of substituents, means that R6, R7 and R8 are independently selected, but also that where an R6, R6 or R8 variable occurs more than once in a molecule, those occurrences are independently selected (e.g., if R is —OR6 wherein R6 is hydrogen, R4 can be —OR6 wherein R6 is lower alkyl).

Compounds of the invention have at least one asymmetric carbon atom and therefore all isomers, including enantiomers and diastereomers are contemplated as being part of this invention. The invention includes d and I l isomers in both pure form and in admixture including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting chiral starting materials or by separating isomers of a compound of formula I. Isomers may also include geometric isomers, e.g. when a double bond is present. All such geometric isomers are contemplated for this invention.

Those skilled in the art will appreciate that for some compounds of formula I, one isomer will show greater pharmacological activity than another isomer.

Compounds of the invention with an amino group can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs front its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base form for purposes of the invention.

Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Cholesterol biosynthesis inhibitors for use in the combination or the present invention include HMG CoA reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin, and Cl-981; HMG CoA synthetase inhibitors, for example L-659,699 ((E,E)-11-[3′-R-(hydroxy-methyl)-4′-oxo-2′-R-oxetanyl]-3,5,7R-trimethyl-2,4-undecadienoic (acid); squalene synthesis inhibitors, for example squalestatin 1; and squalene epoxidase inhibitors, for example, NB-598 ((E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[(3,3′-bithiophen-5-yl)methoxy]benzene-methanamine hydrochloride) and other cholesterol biosynthesis inhibitors such as DMP-565. Preferred HMG CoA reductase inhibitors are lovastatin, pravastatin and simvastatin.

Compounds of formula I can be prepared by known methods, for example those described below and in WO93/02048.


Compounds of formula Ia and Ib, wherein Ar1, Ar2, Ar3, Ar3 X, Y, Z, R1, R2, R3, m, n, p, q and r are as defined above, can be prepared by treatment of an ester of formula III, wherein R10 is lower alkyl such as ethyl or a chiral moiety such as menthyl or 10-(diisopropylsulfonamido)isobornyl, and the remaining variables are as defined above, with a strong base such as lithium diisopropylamide (LDA) in a suitable solvent such as tetrrahydrolithium (THF) at −78° C. A solubilizing agent such as hexamethylphosphoric triamide (HMPA) may optionally be added as a cosolvent. An imine of formula 11, wherein Ar20 and Ar30 are as defined above, is added, the reaction mixture is either warmed to room temperature or maintained at a suitable low temperature such as −78° C. for the appropriate time, followed by quenching with a suitable acid such as 1N HCl. The product is isolated using conventional purification techniques. When a protecting group as defined in Table 1 (below) is present on one or more of the optionally protected groups, an additional step comprising removal of the protecting group by conventional techniques is needed. However, for compounds of formula Ia, Ib, or any compound of formula I wherein a protected hydroxy group Ar10, Ar20, Ar30, R′ or R2′ is an alkoxy or benzyloxy group, such a protecting group need not be removed to obtain a compound of formula I. When a chiral ester of formula III is used, the resulting compound of formula Ia or Ib is not racemic.

Imines of formula II (Ar30—CH═N—Ar20) can be prepared from aldehydes of the formula Ar30—CHO and amines of the formula Ar+—CHO and Ar20—NH2 by procedures well known in the art. Aldehydes of formula Ar+ Ar30—CHO and amines of formula Ar20—NH2 are commercially available or can be prepared via known procedures.


Compounds of formula Ic and Id, wherein the variables are as defined above, can be prepared by a process comprising the following steps:

(a) Treat a lactone of formula IV, wherein the variables are as defined above, with a strong base such as an alkyllithium (e.g., n-butyl-lithium), a metal hydride (e.g., sodium hydride), a metal alkoxide (e.g., sodium methoxide), a metal halide (e.g., TiCl4), metal exchange of the lithium enolate with a metal halide (e.g., zinc chloride), metal exchange of the lithium enolate with a metal alkyl (e.g., 9-borabicyclononyl triflate), or, preferably, a metalamide (e.g., LDA), in a suitable anhydrous organic solvent such as dry THF, ether or benzene, in a dry, inert atmosphere, e.g., under nitrogen. The reaction is carried out at about 0° C. to about −85° C., preferably about −78° C., over a period of about 5 to 60 minutes, preferably about 30 minutes. 1-50% of solubilizing cosolvents may optionally be added, preferably about 10% HMPA.

(b) Add an imine of formula 11, wherein Ar20 and Ar30 are as defined above, to the product of step (a) over a period of 5 to 60 minutes, preferably 30 minutes, maintaining the reaction mixture at about 0° C. to about −85° C., preferably about −78° C., for 1 to 12 hours, preferably about 3 hours, or warming the reaction mixture over that time period at a rate of about 10° C. per hour to about 70° C. per hour, preferably about 30° C. per hour, to a temperature of about 20° C.

(c) Quench the reaction with a suitable acid such as HCl (1N).

(d) The protecting groups on R′, R2′, Ar10, Ar20 and Ar30, when present, are removed, if desired, by methods well known in the art, for example silyl protecting groups are removed by treatment with fluoride.

e) Compounds of formula I wherein any of R and R2, when present, are OR6 wherein R6 is hydrogen, can be converted by well known methods to other compounds of formula I wherein R and R2 are functionalized, i.e., are independently selected from the group consisting of OR6a, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7, wherein R6, R7 and R9 are as defined above and R6a is lower alkyl, aryl, or aryl-lower alkyl. For example, treatment of the alcohol with an alkyl halide in the presence of a suitable base such as NaH will afford alkoxy-substituted compounds (i.e., R or R2 is OR6, wherein R6 is lower alkyl); treatment of the alcohol with an acylating agent such as acetylchloride will result in compounds wherein R or R2 is —OC(O)R6; treatment of the alcohol with phosgene followed by an alcohol of the formula HOR9 affords compounds substituted with a —OC (O)OR9 group; and treatment of the alcohol with phosgene followed by an amine of the formula HNR6R7 affords compounds wherein R or R2 is —OC(O)NR6R7. Compounds of formula I wherein any Ar1, Ar2 or Ar3 has a hydroxy or amino group can be similarly functionalized to obtain other compounds of formula 1, i.e., wherein R4 and R5 are independently —OR6a, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8 or —NR6SO2R9.

The product of step c, d or e is isolated using conventional purification techniques such as extraction, crystallization or, preferably, silica gel 60 chromatography. When a chiral lactone is used, the resulting compound of formula Ic or Id is not racemic.

Using the procedure described in steps (a)-(e), lactones of formula IVa can be used to prepare compounds of formula Ig and Ih, provided that when n and r are each zero, p is 1-4:

Lactones of formulae IV and IVa are known in the art or can be prepared by methods well known in the art. See, for example, U.S. Pat. No. 4,375,475 and J. Agric. Food Chem., 30 (5) (1982) p. 920-4.


Azetidinones of formula V, wherein Ar20 and Ar30 are as defined above, can be reacted to form compounds of formula Ie and If i.e., compounds of formula I wherein r is 1, R2 is hydroxy, and p is zero) by treatment of azetidinone V with a strong base such as lithium iosoproptylcyclohexylamide isopropylcyclohexylamide in a suitable solvent such as THF in the presence or absent absence of HMPA at −78° C., followed by the addition of an aldehyde or ketone of VI, wherein Ar10, X, Y, R′, R1, R3, m, n and q are as defined above. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary.

This process provides several of the possible diasteromers which can be separated by a combination of crystallization, silica gel chromatography and HPLC, using techniques well known in the art. The remaining diastereomers can be obtained by inversion reactions such as the Mitsunobu reaction sequence outlined below, wherein partial structures of formula If are shown:


In the above known process, DEAD is diethylazodicarboxylate and PPh3 is triphenylphosphine. The reactants are stirred at room temperature overnight and the resultant formate ester is converted to the corresponding hydroxy compound with the desired stereochemistry.


Compounds of formula Ia as defined above can be prepared by reacting a chiral auxiliary such as the compound of formula VIII with an activated carboxylic acid derivative of formula VII, for example an acid chloride (L═Cl), a mixed anhydride formed with phenyl phosphorodichloridate (L═OP(O)(Cl)OPh), an N-methyl-pyridinium ester formed from the reaction of an acid with N-methyl-2-chloropyridinium iodide (L=2-oxy-N-methylpyridinium iodide), and a 2-thiopyridyl ester formed from the reaction of an acid chloride and 2-thiopyridine, wherein the remaining variables are as defined above; enolizing the resultant product, for example with TiCl4 and tetramethylethylenediamine (TMEDA); condensing with an aldehyde, Ar30CHO; hydrolyzing to the corresponding acid, then reacting the compound of the formula IX with an amine, Ar20NH2; and cyclizing the resultant compound of formula X, with, for example a trialkylphosphine and a dialkylazodicarbo)ylate. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. This procedure is described in detail in WO93/102048 WO93/02048.


Compounds of formula Ia as defined above can also be prepared treatment of an imine of formula 11, II, wherein Ar20 and Ar30 are as defined above, with an activated carboxylic acid derivative of formula VII as defined above in the presence of a tertiary amine base such as triethylamine, tributylamine or diethylisopropylamine in an inert solvent such as CH2Cl2. Again, as in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. Use of other bases, e.g., pyridine, favors formation of compounds of formula Ib.

In the first step, compound XII is dissolved in a suitable solvent, e.g., anhydrous CH2Cl2, and treated with a Lewis acid, e.g., TiCl4 at about −60° C. to 0° C., preferably at about −25° C., under a dry, inert atmosphere, e.g., argon. A tertiary amine base such as TMEDA is added and the mixture stirred at about −60° C. to 0° C., preferably at about −25° C. to −15° C., for a period of about 1 h. An imine of formula Ar30CH═NAr20 is added neat or optionally as a solution in a suitable solvent, e.g. anhydrous CH2Cl2, over a period of about 5 min, and the reaction is stirred vigorously at about −60° C. to 0° C., preferably at about −25° C. to −15° C., for about 3 to 6 h, preferably about 4 h or until the reaction is complete by TLC. An acid, e.g. acetic acid, is added to reaction at the reaction temperature and the mixture is allowed to warm to room temperature slowly with stirring for about 1-3 hours, preferably about 2 hours. The compound of formula XII is isolated by extraction with a suitable solvent, e.g. CH2Cl2, then purified by crystallization or silica gel chromatography.

In the second step, the product is treated with a strong non-nucleophilic base, such as sodium or lithium bistrimethylsilylamide at about −78° C. to 100° C. After reaction, the mixture is poured into aqueous tartaric acid and the product isolated from the organic layer. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. This process, including the preparation of the starting material of formula XII, is also described in greater detail in WO93/02048.


Compound of formula Ig′ and Ih′ (i.e., compounds of formula I wherein R is OH), wherein R2′ is a protected hydroxy group as defined above, and the remaining variables are as defined above, can be prepared by reacting an imine of formula 11 II and a carboxylic acid derivative of formula XIV, wherein the variables are as defined above, according to method D, followed by oxidation of the resultant halide of formula XV by treatment with an oxidizing agent such as trimethylamine oxide, CrO3 or ozone in a solvent such as DMSO. The resultant aldehyde or ketone of formula XVI is then reacted with an aryl organometallic reagent (e.g., Ar10XmMgBr, Ar10XmLi, Ar10XmMgCl or Ar10XmCeCl2) to obtain a compound of formula Ig′ or Ih′. As described above, the Ar10, Ar20, Ar30 and R2′ substituents can be converted to the desired Ar1, Ar2, Ar3 and R2 substituents by procedures well known in the art.


Compounds of formula Ii having a hydroxy substituent on the side chain adjacent to the Ar1 group (i.e., compounds of formula I wherein m is 0) can be prepared by heating a compound of formula XVII, prepared by Method D, above, wherein the variables are as defined above, for about 1-6 hours at about 60° C. to 100° C. with a halogenating agent such as N-bromosuccinimide (NBS) in a suitable solvent such as CCl4 in the presence of an initiating agent such as benzoyl peroxide. The resultant compound of formula XVIII, wherein Hal is Cl, Br or I and the remaining variables are as defined above, is then heated in a suitable solvent such as CH2Cl2 with a tetraalkyl-ammonium salt such as tetra n-butyl-ammonium hydroxide (n-Bu4NOH) to obtain the compound of formula Ia. Alternatively, compound XVIII can be heated in a suitable solvent such as CH2Cl2 with tetra n-butylammonium trifluoroacetate (n-Bu4NOC(O)CF3) followed by treatment with a mild base such as ethanol saturated with NH3 NH3 to obtain compound Ii,

Compounds of formula Ij (i.e., compounds of formula I wherein R is OH, R1 is H and q is 1) are prepared from compound XIX in 2 steps. First, a compound of formula XIX, wherein the variables are a defined above, is dissolved in a suitable anhydrous solvent, e.g. THF, at about −20° C. to about 22° C., preferably at about 0° C. under a dry inert atmosphere, e.g. argon and adding a transition metal source, e.g. tetrakis(triphenylphosphine)-palladium or palladium acetate/triphenyl phosphine. An organometallic of formula Ar10-Xmm-Met, wherein in Ar10, X and m are as defined above and Met is, for example, ZnCl or B(OH)2, is added to the reaction mixture at about −20° C. to about 22° C., preferably at about 0° C., the reaction mixture is stirred for about 15 min to 4 h, preferably about 1 h, and is then allowed to warm to about 22° C. Addition of dilute acid, e.g. 1N HCl, followed by extraction with a suitable organic solvent, e.g. ethyl acetate (EtOAc), produces compound XX.

The ketone of-formula XX is dissolved in a suitable solvent e.g. CH3OH a hydrogenation catalyst is added, e.g. Pd on carbon, and the mixture is exposed to H2 gas under a pressure of about 14 psi to 100 psi, preferably about 60 psi for about 1 to 24 h, preferably, about 16 h. The hydrogenation catalyst is removed by filtration and the solvent is removed in vacuo to produce a compound Ij as a mixture of alcohol diastereomers which can be separated by conventional means.

Alternatively, a ketone of formula XX is dissolved in a suitable solvent, e.g. THF, about −40° C. to about 22° C., preferably at about 0° C., and a suitable reducing agent such as NaBH4, a substituted borohydride (e.g., [cbz-proline]3BHNa) or a borane is added, optionally in the presence of a suitable chiral promotor present either in catalytic or stoichiometric amounts, e.g., chiral borane of structures:


Addition of dilute acid, e.g., 1N HCl, followed by extraction with a suitable solvent produces compounds of formula Ij. As above, protecting groups at Ar10, Ar20, Ar30 and R2′ are removed as necessary. When either a chiral reagent or a chiral promotor is used, the resulting product is non-racemic.

Compounds of formula XIX can be prepared by a multi-step procedure as represented below:

Compounds of formula XXI, wherein R10 is lower alkyl and the remaining variables are as defined above, are commercially available or can be prepared by treating the corresponding carboxylic acid (i.e., compounds wherein the Cl is replaced by a hydroxy group) with a chlorinating agent, e.g. SOCl2 or oxalyl chloride, under a dry atmosphere, neat or in a suitable inert organic solvent, e.g. toluene at about 40° C. to 110° C., preferably about 70° C.; alternatively, a catalyst made be added, e.g. dimethylformamide (DMF), the reaction is conducted at about 22° C., and the solvent and excess reagents are removed in vacuo. The compound XXI is reacted with a chiral auxiliary such as (S)-4-phenyl-2-oxazolidinone according to the following procedure; a chiral auxiliary is treated with a strong base such as an alkyllithium, a metal hydride or a tertiary amine base such as triethylamine, in a suitable anhydrous organic solvent, e.g., dry THF, under a dry, inert atmosphere, e.g. argon at about −85° C., to 22° C., preferably about 0° C., for about 10 min to 60 min, preferably about 30 minutes. The resulting anion is reacted, without isolation, with compound XXI in a suitable anhydrous organic solvent, e.g. dry THF, under a dry, inert atmosphere, e.g. argon at about −85° C. to about 22° C., preferably 0° C., for about 30 min to 60 min, preferably 30 min. The reaction is warmed to about 220° C. and continued for 1 to 12 h, preferably 6 h. Water is added and compound XXII is isolated by extraction and purified by crystallization.

The compound of formula XXII is treated in the same manner as described in step 1 of Method E to obtain a compound XXIII.

Azetidinone ring closure can be accomplished by alternative procedures. By one method, a compound of formula XXIII is treated with a strong non-nucleophilic base, such as sodium or lithium-bistrimethylsilylamide, in a suitable inert organic solvent, e.g. CH2Cl2, at about −78° C. to about 10° C., preferably about 0° C. The mixture is stirred for about 1 to 2 hours while gradually warming to about 22° C. Compound XXIV is isolated by conventional extraction with CH2Cl2. In another, two-step method, a compound of formula XXIII is first treated with mild silylating agent, e.g. N,O-bis(trimethylsilyl)acetamide at about 0° C. to about 100° C., preferably about 40° C. for about 10 min to 60 min, preferably 30 min, then treated with a fluoride anion source, e.g., tetrabutylammonium fluoride (TBAF), at about 0° C. to about 100° C., preferably 40° C., and allowed to stir for about 0.5 to about 4 hours, preferably about 2 hours. Compound XXIV is isolated by conventional extraction methods.

The compounds of formula XXIV is hydrolysed by a suitable base, e.g. LiOH, in a suitable solvent, e.g. 66% CH3OH/water at about 0° C. to about 50° C., preferably 22° C., for about 1 to 4 hours, preferably 2 hours, then extracted with a suitable solvent, e.g. EtOAc. The resulting acid is converted to the acid chloride as described above by treatment with a chlorination agent, e.g. oxalyl chloride, to afford compound

Compounds of formula Ik, wherein Ar1, Ar2, Ar3 and R1 are as defined above, one of X″ and Y″ is —CH2CH2— and the other is selected from the group consisting of —CH2CH2—, —CH2—, —CH(lower alkyl)-, —CH(dilower alkyl) and a bond, are prepared by oxidation of an alkene of formula XXV, wherein one of X′ and Y′ is —CH═CH— and the other is —CH═CH—, —CH2—, —CH2CH2—, —CH(lower alkyl)-, —CH(dilower alkyl) or a bond, and the remaining variables are as defined above, can be prepared by the following two step procedure.

A compound of formula XXV, which can be prepared by Method D, above, is treated with an oxidizing agent such as SeO2, phenylselenic anhydride or CrO3 in a suitable solvent such as dioxane at about 22° to 100° C. for about 0.5 to 12 hours. After the starting material is consumed as determined by TLC, or 12 hours, the reaction is cooled to about 22° C. and the product XXVI is isolated by extraction.

In the second step, an allylic alcohol of formula XXVI is dissolved in a suitable solvent, e.g., EtOAc, a hydrogenation catalyst added, e.g., Pd on carbon, and the mixture is exposed to H2 gas under a pressure of about 14 psi to 60 psi for about 1 to 12 hours. The hydrogenation catalyst is removed in vacuo to obtain a compound of formula Ik.


Alcohols of formula Im and In (i.e., compounds of formula I where r is 1, R2 is —OH, R3 is hydrogen and p is 0) can be selectively obtained front ketones of formula XXVII in three steps comprising bromination, reduction and debromination. Since the stereochemistry of the major isomers of alcohols XXIXa and XXIXb are different, one can selectively prepare either diastereomeric alcohol.

In the above process, a ketone of formula XXVII, which can be prepared by oxidation of the corresponding hydroxy compound by well known methods, is halogenated, for example by treatment in an inert solvent, e.g., THF, with NaH followed by N-bromosuccinimide, to obtain a mixture of 3-bromo-ketone compounds XXVIII (a and b). Compounds 15 XXVIIIa and XXVIIIb are then separately reduced to the corresponding alcohols, for example by treatment with magnesium trifluoroacetate (Mg(TFA)2) and t-butylamine borane (t-Bu—NH2—BH3) in an inert solvent such as THF at a temperature of about −78° C. to 0° C. The resultant alcohols XXIX are dehalogenated by treatment with tris(trimethylsilyl)silane ((TMS)3SiH) in a solvent such as toluene in the presence of a radical initiator such as 2,2′-azobisisobutyronitrile (AIBN) to obtain a mixture of isomers Im and In which can be separated into individual enantiomers by conventional means, e.g., HPLC. Again, protecting groups at Ar10, Ar20, Ar30 and R′ are removed as necessary.

Starting compounds III, V, VI, VII, VIII, XIV, XVII, XXI and XXV are all either commercially available or well known in the art and can be prepared via known methods.

Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction. The following Table 1 shows some typical protecting groups:

TABLE I
Group to be Group to be Protected and
Protected Protecting Group
—COOH —COOalkyl, —COObenzyl, —COOphenyl
—NH2
—OH
—OSi(CH3)3, or —OCH2phenyl

We have found that the compounds of this invention lower serum lipid levels, in particular serum cholesterol levels. Compounds of this invention have been found to inhibit the intestinal absorption of cholesterol and to significantly reduce the formation of liver cholesteryl esters in animal models. Thus, compounds of this invention are hypocholesterolemic agents by virtue of their ability to inhibit the intestinal absorption and/or esterification of cholesterol; they are, therefore, useful in the treatment and prevention of atherosclerosis in mammals, in particular in humans.

The in vivo activity of the compounds of formula I can be determined by the following procedure:

In Vivo Assay of Hypoligidemic Hypolipidemic Agents Using the Hyperlipidemic Hamster

Hamsters are separated into groups of six and given a controlled cholesterol diet (Purina Chow #5001 containing 0.5% cholesterol) for seven days. Diet consumption is monitored to determine dietary cholesterol exposure in the face of test compounds. The animals are dosed with the test compound once daily beginning with the initiation of diet. Dosing is by oral gavage of 0.2 mL of corn oil alone (control group) or solution (or suspension) of test compound in corn oil. All animals moribund or in poor physical condition are euthanized. After seven days, the animals are anesthetized by intramuscular (IM) injection of ketamine and sacrificed by decapitation. Blood is collected into vacutainer tubes containing EDTA for plasma lipid analysis and the liver excised for tissue lipid analysis. Lipid analysis is conducted as per published procedures (Schnitzer-Polokoff, R., et al. Comp. Biochem. Physiol., 99A, 4 (1991), p. 665-670) and data is reported as percent reduction of lipid versus control.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. The compounds of formula I can be administered in any conventional dosage form, preferably an oral dosage form such as a capsule, tablet, powder, cachet, suspension or solution. The formulations and pharmaceutical compositions can be prepared using conventional pharmaceutically acceptable excipients and additives and conventional techniques. Such pharmaceutically acceptable excipients and additives include non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.

The daily hypocholesteremic dose of a compound of formula I is about 0.1 to about 30 mg/kg of body weight per day, preferably about 0.1 to about 15 mg/kg. For an average body weight of 70 kg, the dosage level is therefore from about 5 mg to about 1000 mg of drug per day, given in a single dose of 2-4 divided doses. The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

For the combinations of this invention wherein the hydroxy substituted azetidinone is administered in combination with a cholesterol biosynthesis inhibitor, the typical daily dose of the cholesterol biosynthesis inhibitor is 0.1 to 80 mg/kg of mammalian weight per day administered in single or divided dosages, usually once or twice a day; for example, for HMG CoA reductase inhibitors, about 10 to about 40 mg per dose is given 1 to 2 times a day, giving a total daily dose of about 10 to 80 mg per day, and for the other cholesterol biosynthesis inhibitors, about 1 to 1000 mg per dose is given 1 to 2 times a day, giving a total daily dose of about 1 mg to about 200 mg per day. The exact dose of any component of the combination to be administered is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

Where the components of a combination are administered separately, the number of doses of each component given per day may not necessarily be the same, e.g. where one component may have a greater duration of activity, and will therefore need to be administered less frequently.

Since the present invention relates to the reduction of plasma cholesterol levels by treatment with a combination of active ingredients wherein said active ingredients may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. That is, a kit is contemplated wherein two separate units are combined: a cholesterol biosynthesis inhibitor pharmaceutical composition and a hydroxy substituted azetidinone cholesterol absorption inhibitor pharmaceutical composition. The kit will preferably include directions for the administration of the separate components. The kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. oral and parenteral) or are administered at different dosage intervals.

Following are examples of preparing compounds of formula I. The stereochemistry listed is relative stereochemistry unless otherwise noted. The terms cis and trans refer to the relative orientations at the azetidinone 3- and 4-positions unless otherwise indicated. The term “J” refers to the proton NMR coupling constant in hertz (Hz) between the 3- and 4-substituted protons of the azetidinone. All NMR data is of CDCl3 solution unless otherwise indicated.

Freshly prepare a solution of lithium diisopropylamide (LDA) by dissolving diisopropylamine (1.19 g, 11.8 mmol) in anhydrous THF (20 ml) at −78° C. under argon. Add n-butyllithium (4.9 ml, 11.8 mmol, 2.4M in hexanes) and stir for 0.5 h at −78° C. To this cold solution add, 4phenylbutyrolactone (1.75 g, 10.8 mmol) in THF (4 ml) over 0.25 h, keeping the reaction temperature below −65° C. Stir at −78° C. for 0.25 h, then add 4-methoxybenzylidine anisidine (2.33 g, 11.0 mmol) in THF (8 ml) over 1 h at −78° C. Warm the reaction slowly to −50° C. over 1 h. Quench the reaction at low temperature with 1N HCl (12 ml). Partition the reaction mixture between ether and 1N HCl, wash the ether layer with water, combine the ether extracts, dry over MgSO4 and concentrate in vacuo. Crystallize the crude reaction residue (3.0 g) from EtOAc-ether to obtain 1.54 g of compound A. Reconcentrate the filtrate and chromatograph on silica gel 60, eluting with 4:1 EtOAc-hexane, and isolate additional compound A (0.385 g) as well as compound B (0.420 g).

Compound A: mp 218°-220° C.; IR 1730 cm-1; CI (M−H) 374; J=5.9 Hz.

Compound B: mp 74°-76° C.; IR 1730 cm-1; CI (M+H) 374; J=2.3 Hz.

Using a similar procedure and appropriate starting materials, prepare compound 1C:

Cl(M + H) 464, J = 2.3 Hz

EXAMPLE 2

To a solution of compound A from Example 1 (0.5 g, 1.3 mmol) in anhydrous pyridine (2.7 ml), add acetic anhydride (0.63 ml, 6.7 mmol). Stir for 16 h, dilute with CH2Cl2 and wash 3× with 1N HCl 1× with NaCl (sat'd) and 1× with water. Concentrate the organic layer to dryness and crystallize the residue from EtOAc to obtain the title compound (0.46 g), mp 167°-169° C.; IR 1745 cm-1; EI (M+) 415; J=5.9 Hz.

EXAMPLE 3

Freshly prepare a solution of lithium isopropylcyclohexylamide (LICA) by adding n-butyllithium (2.84 mL of a 1.6M solution) to 5 a solution of isopropylcyclohexylamine (0.75 mL) in THF (100 mL) at −78° C. Dissolve N-phenyl-4-(4-methoxyphenyl)-2-azetidinone (1.0 g) in THF (8 mL) and slowly add to the LICA solution at −78° C. After stirring for 20 min, add hydrocinnamaldehyde (0.54 g) and stir the reaction mixture at −78° C. for 4 h. Quench the reaction with 10% KHSO4 and extract the product with EtOAc. Separate the organic layer, wash with water and NaCl (sat'd). Concentrate the extract and purify the resultant residue on a silica gel 60 column, eluting with EtOAc:hexane (15:85) to obtain 1.15 g of product as a mixture of diastereomers. Separate the diastereomers by HPLC on a silica gel column to give three diastereomers 3A, 3B and 3C:

3A 1H in CDCl3: 7.32-7.18(m, 11H); 708-6.99 (m, 1H); 6.89(d, J = 9 Hz, 2H); 4.80(d, J = 2.4 Hz, 1H); 4.10-4.00(m, 1H); 3.79(s. 3H); 3.20-3.16(m, 1H); 2.90-2.67(m, 2H); 2.15-1.85(m, 3H)
3B 1H in CDCl3: 7.35-7.10(m, 11H); 7,08-6.99 (m, 1H); 6.89(d, J = 9 Hz, 2H); 5.09(d, J = 2.4 Hz, 1H); 4.26-4.14(m, 1H); 3.79(s, 3H); 3.21-3.14(m, 1H); 2.89-2.57(m, 2H); 2.40-1.85(m, 3H)
3C 1H in CDCl3: 7.30-7.00(m, 10H); 6.99 (d, J = 8 Hz, 2H); 6.83(d, J = 9 Hz, 2H); 5.12(d, J = 5.5 Hz, 1H); 3.82(s, 3H); 3.75-3.63(m, 1H); 3.52(dd, J = 9.5 Hz, 1H); 2.71-2.57(m, 1H); 2.49-2.33(m, 1H); 1.68-1.50(m, 1H); 1.47-1.31)m, 1H)

The 3A, 3B and 3C, diastereomers were further separated according to the following reaction scheme, wherein partial structures are shown:


(The following CD spectra data [θ] are all obtained in CH3OH.)

3D) [θ]227nM=+2.0×104 cm2/dM; [θ]241nM=−4.6×104 cm2/dM. Elemental analysis calc for C25H25NO3−0.25 H2O: C 76.6; H 6.56 N 3.57. found: C 76.66; H 6.49; N 3.64.

3E) [θ]227nM=−1.95×104 cm2/dM; [θ]241nM=+4.45×104 cm2/dM. Elemental analysis calc for C25H25NO3.0.5 H2O: C 75.73; H 6.61; N 3.53. found: C 75.66; H 6.41; N 3.60.

3F) [θ]226nM=+1.97×104 cm2/dM; [θ]240nM=−5.22×104 cm2/dM. Elemental analysis calc for C25H25NO3: C 77.48; H 6.5-1; N 3.62. found: C 77.44; H 6.53; N 3.70.

3G) [θ]226nM=−1.78×104 cm2/dM; [θ]241nM=+4.78×104 cm2/dM (CIMS 388 M+H).

3H) [θ]226nM=+2.24×104 cm2/dM; [θ]241nM=−5.4×104 cm2/dM. [α]D 25=−54.4° (2.5 mg/ml CH3OH) Elemental analysis calc for C25H25NO3: C 77.48; H 6.51; N 3.62. found: C 77.11; H 6.50; N 3.72.

3I) [θ]226nM=−2.05×104 cm2/dM; [θ]241nM=+5.2×104 cm2/dM. (CIMS 388 M+H).

Add DEAD (0.11 ml) to a solution of compound 3H (132 mg), PPh3 (0.18 g) and HCO2H (39 ml) in THF (5 ml). Stir at room temperatq temperature overnight, then partition the reaction mixture between Et2O and H2O. Wash (brine) and dry (MgSO4) the organic layer and concentrate to dryness. Flash chromatograph the residue using EtOAc:Hex (1:4) to obtain the formate ester. Dissolve this in CH3OH and add 4 drops of conc. HCl. After 4 h, concentrate in vacuo and flash chromatograph the residue using EtOAc:Hex (1:3) to obtain 3J. [θ]224nM=+2.54×103 cm2/dM;

[θ]239nM=+5.70×104 cm2/dM; [α]D 20=−157.6° (2.5 mg/ml CH3OH)

Using the procedure described for 3J, treat compound 3I to obtain 3K. [θ]222nM=−3.4×103 cm2/dM; [α]240nM=−5.6×104 cm2/dM. [α]D 20=+167.2° (2.5 mg/ml CH3OH)

Using the procedure described above for preparing compounds 3A and 3B, treat N-phenyl-4-(4-methoxyphenyl)-2-azetidinone with LICA followed by 2-naphthaldehyde to obtain the diastereomers 3L and 3M:

3L mp 137- 138° C.
3M mp 150- 151° C.

EXAMPLE 4


Method 1:

Step 1) To a refluxing solution of of 4-methoxyberizylidene anisidine (10.0 g, 41.5 mmol) and tributylamine (20.8 ml. 87 mmol) in toluene (100 ml), add 5-bromovaleroyl chloride (8.5 g, 43, mmol) in toluene (20 ml) dropwise over 2 h. Stir the reaction mixture at 80° C. for 12 h, cool to room temperature, wash 3× with 1 N HCl, 1× with water and dry the organic layer over MgSO4. Purify by silica gel chromatography, eluting with ethyl acetate:hexane (4:1) to obtain 5.1 g of (3R, 4S)-1,4-bis(4-methoxyphenyl)-3-(3-bromoproyl)-2-azetidinone (relative stereochemistry), mp 70°-73° C., E1 (M+) 404; J=2.3 Hz.

Step 2) To a solution of the product of step 1 (5.1 g, 12.6 mmol) in (CH3)2SO (20 ml), add (CH3)3N(O) (2.39 g, 31.9 mmol). Heat the mixture at 60° C. for 3 h, cool to room temperature, dilute with EtOAc, and wash 3× with water. Combine the aqueous fractions and extract with EtOAc. Combine the organic fractions and concentrate. Purify the crude product by silica gel chromatography, eluting with EtOAc:hexane (1:1) to obtain 1.4 g (3R, 4S)-1,4-bis-(4-methoxyphenyl)-2-oxo-3-azetidine-propanol (relative stereochemistry), an oil; EI (M+) 339; J=2.3 Hz.

Step 3) To a solution of the product of step 2 (0.71340.734 g, 2.2 mmol) in THF (4 ml) at 0° C., add phenylmagnesium bromide (2.4 ml, 2.4 mmol, 1.0 M in THF) over 0.25 h. After 1 h at 0° C., add water (5 ml), separate the layers, wash the organic layer 1 × with 1N HCl, dry with MgSO4 and concentrate to an oil. Purify by silica gel chromatography, eluting with EtOAc:hexane (2:1) to obtain 0.372 g of the title compound (mix of diastereomers) as an oil. CI (M+H) 418.

Separation of diastereomers: Apply the diastereomeric mixture from step 3 to a Chiralcel OD (Chiral Technologies Corp, Pa.) chromatography column, eluting with hexane:ethanol (9:1) to obtain enantiomerically pure (>98%) diastereomers as follows:


Method 2:

Step 1) To a solution of 1,4-(S)-bis(4-methoxyphenyl)-3-(3(R)-phenylpropyl)-2-azetidinone (5.04 g, 0.013 mole) in CCl4 (20 ml) at 80° C., add NBS (2.76 g, 0.0155 mole) and benzoyl peroxide (0.24 g, 1.0 mmole) in three equal portions over 1 h. Follow the reaction by TLC (4:1 hexane:EtOAc). Cool the reaction to 22° C., add NaHSO4, separate the layers and wash the organic layer 3× with water. Concentrate the organic layer to obtain the crude product.

CI (M+H) 480; 1H in CDCl3 δ PhCH(OH)=5.05 ppm.

Step 2) Dissolve the crude product of Step 1 in CH2Cl2 (30 ml) and add 40% n-BuNOC(O)CF3 in water (30 ml). Reflux the biphasic reaction for 24 h, cool, separate the layers and wash the organic layer 6× with water. Concentrate the organic layer to dryness and immediately redissolve the residue in ethanol saturated with NH3 (10 ml). After 1 h, concentrate the reaction mixture and partially purify by silica gel chromatography. Further purify by HPLC to obtain a 1:1 mixture of compounds 4A and 4B. The mixture can be further purified on a Chiracel OD column to obtain 4A and 4B separately as characterized above.

Using the procedure described in Example 4, Method 2, with 4(S)-(4-acetoxyphenyl)-3(R)-(3-phenylpropyl)-1 -(4-methoxy-phenyl)-2-azetidinone as the starting material, prepare the following compounds:

EXAMPLE 5

To a solution of the product of step 2 of Example 4 (0.230 g, 0.68 mmol) in THF (2 ml), add the reagent derived from treatment of 4-methoxymethylphenyl bromide (0.159 g, 0.736 mmol) in THF (4 ml) at −78° C. with sec-butyllithium (0.6 ml, 0.78 mol, 1.3M in hexanes), followed by CeCl3 (0.186 g, (0.75 mmol). After 4 h, extract the product and purify by chromatography in a manner similar to that described in step 3 of Example 4 to obtain 0.05 g of the title compound (mix of diastereomers) as an oil. CI (M+H) 478.

EXAMPLE 6

Step 1): To a solution of (S)-4-phenyl-2-oxazolidinone (41 g, 0.25 mol) in CH2Cl2 (20 ml), add 4-dimethylaminopyridine (2.5 g, 0.02 mol) and triethylamine (84.7 ml, 0.61 mol) and cool the reaction to 0° C. Add methyl-4-(chloroformyl)butyrate (50 9 g, 0.3 mol) as a solution in CH2Cl2 (375 ml) dropwise over 1 h, and allow the reaction to warm to 22° C. After 17 h, add water and H2SO4 (2N, 100 ml), separate the layers, and wash the organic layer sequentially with NaOH (10%). NaCI (sat'd) and water. Dry the organic layer over MgSO4 and concentrate to obtain a semicrystalline product.

Step 2): To a solution of TiCl4 (18.2 ml, 0.165 mol) in CH2 Cl2 (600 ml) at 0° C., add titanium isopropoxide (16.5 ml, 0.055 mol). After 15 min, add the product of Step 1 (49.0 9, 0.17 mol) as a solution in CH2 Cl2 (100 ml). After 5 min., add diisopropylethylamine (DIPEA) (65.2 ml, 0.37 mol) and stir at 0° C. for 1 h, cool the reaction mixture to −20° C., and add 4-benzyloxybenzylidine(4-fluoro)aniline (114.3 g, 0.37 mol) as a solid. Stir the reaction vigorously for 4 h at −20° C., add acetic acid as a solution in CH2Cl2 dropwise over 15 min, allow the reaction to warnr warm to 0° C., and add H2 SO4 (2N). Stir the reaction an additional 1 h, separate the layers, wash with water, separate and dry the organic layer. Crystallize the crude product from ethanol/water to obtain the pure intermediate.

Step 3): To a solution of the product of Step 2 (8.9 g, 14.9 mmol) in toluene (100 ml) at 50° C., add N,O-bis(trimethylsilyl)acetamide (BSA) (7.50 ml, 30.3 mmol). After 0.5 h, add solid TBAF (0.39 g, 1.5 mmol) and stir the reaction at 50° C. for an additional 3 h. Cool the reaction mixture to 22° C., add CH3OH (10 ml), wash the reaction mixture with HCl (1N), NaHCO3 (1N) and NaCl (sat'd), and dry the organic layer over MgSO4.

Step 4): To a solution of the product of Step 3 (0.94 g, 2.2 mmol) and CH3OH (3 ml), add water (1 ml) and LiOH.H2O (102 gm, 2.4 mmole). Stir the reaction at 22° C. for 1 h and add additional LiOH.H2O (54 mg, 1.3 mmole). After a total of 2 h, add HCl (1N) and EtOAc, separate the layers, dry the organic layer and concentrate in vacuo. To a solution of resultant product (0.91 g, 2.2 mmol) in CH2Cl2 at 22° C., add ClCOCOCl (0.29 ml, 3.3 mmol) and stir for 16 h. Remove the solvent in vacuo.

Step 5): To an efficiently stirred suspension of 4-fluorophenylzinc chloride (4.4 mmol) prepared from 4-fluorophenylmagnesium bromide 5 (1M in THF, 4.4 ml, 4.4 mmol) and ZnCl2 (0.6 g, 4.4 mmol) at 4° C., add tetrakis(triphenylphosphine)palladium (0.25 g, 0.21 mmol) and the product of Step 4 (0.94 g, 2.2 mmol) as a solution in THF (2 ml). Stir the reaction for 1 h at 0° C. and then for 0.5 h at 22° C. Add HCl (1N, 5 ml) and extract with EtOAc. Concentrate the organic layer to an oil and purify by silica gel chromatography to obtain 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-3(R)-(3-oxo-3-phenylpropyl)-2-azetidinone:

HRMS calc'd for C24H19F2NO3=408.1429, found 408.1411.

Step 6): To the product of Step 5 (0.95 g, 1.91 mmol) in THF (3 ml), add (R)-tetrahydro-1-methyl-3,3-diphenyl-1H, 3H-pyrrolo-[1,2-c][1,3,2]oxazaborole (120 mg, 0.43 mmol) and cool the mixture to −20° C. After 5 min, add borohydride-dimethylsulfide complex (2M in THF: 0.85 ml, 1.7 mmol) dropwise over 0.5 h. After a total of 1.5 h, add CH3OH followed by HCl (1 N) and extract the reaction mixture with EtOAc to obtain 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone (compound 6A-1) as an oil. 1H in CDCl3 δ H3=4.68, J=2.3 Hz. CI (M+H) 500.

Use of (S)-tetra-hydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo-[1,2-c][1,3,2] oxazaborole gives the corresponding 3(R)-hydroxypropyl azetidinone (compound 6B-1). 1H in CDCl3 δ H3=4.69, J=2.3 Hz. CI (M+H) 500.

To a solution of compound 6A-1 (0.4 g, 0.8 mmol) in ethanol (2 ml), add 10% Pd/C (0.03 g) and stir the reaction under a pressure (60 psi) of H2 gas for 16 h. Filter the reaction mixture and concentrate the solvent to obtain compound 6A. Mp 164°-166° C.; CI (M+H) 410.

[α]D 25=−28.1° (c 3, CH3OH). Elemental analysis calc'd for C24H21F2NO3; C 70.41; H 5.17; N 3.42; found C 70.25; H 5.19; N 3.54.

Similarly treat compound 6B-1 to obtain compound 6B. Mp 129.5°-132.5° C.; CI (M+H) 410. Elemental analysis calc'd for C24H21F2NO3: C 70.41; H 5.17; N 3.42; found C 70.30; H 5.14; N 3.52.

Step 6′) (Alternative): To a solution of the product of Step 5 (0.14 g, 0.3 mmol) in ethanol (2 ml), add 10% Pd/C (0.03 g) and stir the reaction under a pressure (60 psi) of H2 gas for 16 h. Filter the reaction mixture and concentrate the solvent to afford a 1:1 mixture of compounds 6A and 6B.

Using appropriate starting materials and following the procedure of steps 1-6, prepare the following compounds:

EXAMPLE 7


To a solution of 7a (1.0 g, 2.1 mmol) in dioxane (10 ml), add SeO2 (1.33 g, 11.98 mmol) and water (25 ml, 14 mmol), (0.25 ml, 14 mmol), and heat the reaction to 100° C. After 1 h, cool the reaction to room temperature and isolate by extraction the crude product as a diastereomeric mixture (1:2) of alcohol 7b-A and 7b-R. Purify by HPLC on a Dynamax silica column to separate diastereomers 7b-A and 7b-B.

Diastereomer 7b-A (R): oil; J34=2.3 Hz, δ C H(OH)=4.86 (t); HRMS C32H29NO4 calc.: 491.2097; found: 491.2074.

Diastereomer 7b-E (S): oil; J34=2.3 Hz, δ C H(OH)=5.06 (t); HRMS C32H29NO4 calc.: 491.2097; found: 491.2117.

Step 2): To a solution of diastereomer A from step 1 (58 mg, 0.12 mmol) in EtOAc (2 ml), add 10% Pd on carbon (20 mg) and stir at 22° C. under H2 gas (14 psi) for 12 h. Filter and concentrate to obtain the title compound as a semisolid, m.p. 90°-92° C. J34=2.3 Hz, δ CH(OH)=4.1 (m); HRMS C25H25NO4 calc: 403.1783; found: 403.1792.

EXAMPLE 8

To a solution of the product of Example 4A (90 mg, 0.2 mmol) in CH2Cl2, add acetyl chloride (80 mg, 1.0 mmol) and pyridine (8 mg, 0.1 mmol) and stir at room temperature for 1 h. Add water, separate the layers and isolate the corresponding acetoxy compound, 8A. In a similar manner, treat the products of Examples 4B, 6B and 6A to obtain the following compounds 8B, 8° C. and 8D, respectively:

8A: 1,4(S)-bis(4-methoxyphenyl)-3(R)-(3(R)-acetoxy-3-phenylpropyl)-2-azetidinone. CI (M+H) 460; HRMS C28H29NO5 calc.: 459.2044; found: 459.2045.

8B: 1,4(S)-bis(4-methoxyphenyl)-3(R)-(3(S)-acetoxy-3-phenylpropyl)-2-azetidinone. CI (M+H) 460; HRMS C28H29NO5 calc.: 459.2044; found 459.2048.

8C: 4(S)-(4-acetyloxyphenyl)-3(R)-(3(R)-acetyloxiy-3-(4-fluorophenyl)propyl)-1-(4-fluorophenyl)-2-azetidinone. FAB M:S 493.4; HRMS C28H25F2NO5 calc.: 493.1695; found: 493.1701.

8D: 4(S)-(4-acetyloxyphenyl)-3(R)-(3(S)-acetyloxy-3-(4-fluorophenyl)propyl)-1-(4-fluorophenyl)-2-azetidinone. FAB MS 493.4; HRMS C28H25F2NO5 calc.: 493.1695; found: 493.1694.

Using appropriate starting materials in the procedure of Example 6, prepare 1-(4-chlorophenyl)-3(R)-(hydroxy-3.-(4-chlorophenylpropyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone. Using the procedure of Example 8, prepare the following diacetates 8E and 8F:

EXAMPLE 9

Step 1:

Add pyridinium chlorochromate (2.4 g, 11 mmoles) and CH3CO2Na (approx. 20 mg) to a solution of 1-phenyl-3-(3-phenyl-1-hydroxypropyl)-4-(4-methoxyphenyl)-2-azetidinone (2.35 g, 6.1 mmoles) in CH2Cl2. Stir at room temperature for 18 h, then add silica gel (40 g) and concentrate to dryness. Flash chromatograph the residue using EtOAc:Hex (1:4) to obtain an oil. (1.98 g, yield=85%). 1H NMR 2.85-2.95 (m, 3H), 3.15 (m, H), 3.80 (s, 3H), 4.10 (d, 1H, J 2.6), 5.42 (1H, d, 6.85 (dd, 2H, J 2.8), 7.05 (m, 1H), 7.2-7.35 (m, 11H).

Step 2:

To a solution of the product of Step 1 (1.78 g, 4.62 mmoles) in THF at −10° C., add NaH (115 mg, 4.8 mmoles). After 15 min, add NBS (865 mg, 4.85 mmoles) and stir for 20 min., then add 1N HCl and partition between EtOAc and brine. Separate the organic layer, dry (MgSO4) and concentrate to give an oil. Flash chromatograph the oil using EtOAc:Hex (1:10) to collect first 9a as a foamy solid (830 mg, y=39%, FAB MS 466/464, M+H), and then 9b as a colorless solid (1.1 g, y=51%, FAB MS 466/464, M+H).

Step 3a:

Add Mg(OCOCF3)2.CF3CO2H (7.3 ml of 1M solution is Et2O.) to a solution of 9a (0.68 g, 1.46 mmoles) in THF (5 ml) at −50° C. Stir the reaction 5 min., then add t-Bu—NH2-BH3 (254 mg, 2.92 mmole). After 15 min., allow the reaction to warm to 0° C. over 20 min., add 1N HCl and concentrate in vacuo. Partition the residue between EtOAc and brine. Concentrate the organic layers and dissolve the resultant oil in CH2Cl2:CH3OH (1:1) and add ethanolamine (approx 2 mmoles). After 15 min., concentrate the reaction mixture and partition the residue with EtOAc:1N HCl. Wash (brine) and dry (MgSO4) the organic layer to obtain an oil. Purify this oil by flash chromatography using EtOAc:Hex (1:4) to obtain compound 9a-1, a colorless solid, as a 4:1 mix of diastereomers. 0.52 g, y=76%, SIMS 468/466 (M+H).

Step 3b:

Using compound 9b as the starting material, use a procedure similar to Step 3a with CH2Cl2 as solvent for the preparation of 9b-1 in 80% yield as a 13:1 mixture of diastereomers (SIMS 468/466 M+H).

Step 4a:

Add a solution of 9a-1 (0.27 g, 0.58 mmoles) and AIBN (18 mg, 0.12 mmole) in toluene (40 ml) dropwise over 40 min. to a solution of (TMS)3SiH (1.0 ml) in toluene at 80° C. or 1.5 h. Cool and concentrate the reaction mixture, dissolve the residue in CH3CN and wash 3× with hexane. Concentrate the CH3CN layer to give the title compound as a racemic mixture (0.25 g). Purify this oil by HPLC using a Chiralcel OD column to obtain 3H (major) and 3J (minor).

Step 4b:

Use the procedure of Step 4a, starting with compound 9b-1 to obtain an oil. Purify this by flash chromatography using EtOAc:Hex (1:3) to collect the racemic title compound (y=70%). Purify this oil by HPLC using a Chiralcel OD column to obtain 3J (major) and 3H (minor).

EXAMPLE 10

Step 1:

Follow the procedure of Example 3, using 1-(4-fluorophenyl-4-(4-t-butyldimethylsilyloxyphenyl)-2-azetidinone to obtain 1-(4-fluorophenyl-3-(3-phenyl-1-hydroxypropyl) 4-(4-t-butyldimethylsilyl-oxyphenyl)-2-azetidinone.

Step 2:

Treat a solution of the cis-azetidinone of Step 1 (0.25 g) in CH3CN CH3CN (21 ml) with 48% aqueous HF (2.5 ml). After 18 h, dilute the reaction mixture with cold H2O and extract with Et2O. Wash (2× H2O, dilute NaHCO3 and brine), dry (MgSO4) and concentrate the Et2O layer. Crystallize the residue from EtOAc:hexane (1:2) to obtain the title compound as colorless needles (123 mg, y=64%), mp 168°-171° C. Elemental analysis calc for C24H22O3FN: C 73.64; H 5.66; N 3.58. found C 73.32; H 5.65; N 3.68.

The following formulations exemplify some of the dosage of this invention. In each the term “active compound” designates a compound of formula I.

EXAMPLE A

Tablets
No. Ingredient mg/tablet mg/tablet
1 Active Compound 100 500
1 Lactose USP 122 113
3 Corn Starch, Food Grade, as a 10% 30 40
paste in Purified Water
4 Corn Starch, Food Grade 45 40
5 Magnesium Stearate 3 7
Total 300 700

Method of Manufacture

Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., ¼′, 0.63 cm) if necessary. Dry the cl damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine.

EXAMPLE B

Capsules
No. Ingredient mg/tablet mg/tablet
1 Active Compound 100 500
2 Lactose USP 106 123
3 Corn Starch, Food Grade 40 70
4 Magnesium Stearate NF 4 7
Total 250 700

Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

Representative formulations comprising a cholesterol biosynthesis inhibitor are well known in the art. It is contemplated that where the two active ingredients are administered as a single composition, the dosage forms disclosed above for substituted azetidinone compounds may readily be modified using the knowledge of one skilled in the art.

Using the test procedures described above, the following in vivo data were obtained for the exemplified compounds. Data is reported as percent change (i.e., percent reduction in cholesterol esters) versus control, therefore, negative numbers indicate a positive lipid-lowering effect.

% Reduction
Serum Cholest. Dose
Ex. # Cholest. Esters mg/kg
1A −2.3 0 50
1B −15 −39 50
1C 14 0 50
2 0 0 50
3A −31 −69 50
3C −60 −92 50
3D −17 −61 10
3E 0 0 10
3F −29 −77 10
3G −16 −38 10
3H −41 −86 10
3I 0 −22 10
3J 0 0 3
3K 0 0 10
3L −15 −21 10
3M 0 −22 10
4A 0 −54 5
4B −37 −89 8
4C −12.5 0 3
4D 9 0 7
4E 0 −46 3
4F −29 −95 3
5 0 −64 10
6A −59 −95 1
6A-1 −43 −93 1
6B −40 −92 3
6C 0 −48 3
6D −46 −95 10
8A 0 −44 3
8B −50 −95 3
8C −14 −37 1
8D −49 −98 1
8E −22 −66 3
8F −43 −94 1
10 −26 −77 3

Claims (13)

1. A compound represented by the formula
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are independently selected from the group consisting of —CH2—, —CH(lower alkyl)- and —C(dilower alkyl)-;
R and R2 are independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7;
R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
q is 0 or 1; r is 0 or 1; m, n and p are independently 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from consisting of lower alkyl, —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, -(lower alkylene)COOR6, —CH═CH—COOR6, —CF3, —CN, —NO2 and halogen;
R5 is 1-5 substituents independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and —CH═CH—COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and
R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
2. A compound of claim 1 wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl and Ar3 is R5-substituted phenyl.
3. A compound of claim 2 represented by the formula
or a pharmaceutically acceptable salt thereof, wherein;
Ar1 is R4-substituted phenyl wherein R4 is halogen; Ar2 is R4-substituted phenyl) wherein R4 is halogen or —OR6, wherein R6 is lower alkyl or hydrogen; and Ar3 is R5-substituted phenyl, wherein R5 is —OR6, wherein R6 R6 is lower alkyl or hydrogen;
X, Y and Z are independently selected from the group consisting of —CH2—, —CH(lower alkyl)— and —C(dilower alkyl)—;
R and R2 are independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7;
R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
q is 0 or 1; r is 0 or 1; m, n and p are independently 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R6 and R7 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and
R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
4. A compound of claim 1 wherein X, Y and Z are each —CH2—; R1 and R3 are each hydrogen; R and R2 are each —OR6, wherein R6 is hydrogen; and the sum of m, n, p, q and r is 2, 3 or 4.
5. A compound of claim 1 wherein m, n and r are each zero, q is 1 and p is 2.
6. A compound of claim 1 wherein p, q and n are each zero, r is 1 and m is 2 or 3.
7. A compound selected from the group consisting of
rel 3(R)-(2(R)-hydroxy-2-phenylethyl)-4(R)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
rel 3(R)-(2(R)-hydroxy-2-phenylethyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(S)-(1(S)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(S)-(1(R)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(R)-(1(R)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
rel-3(R)-[(S)-hydroxy-(2-naphthalenyl)methyl]-4(S)-(4-methoxyphenyl)-1-phenyl)-1-phenyl-2-azetidinone;
rel-3(R)-[(R)-hydroxy-(2-naphthalenyl)methyl]-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(R)-(3(R)-hydroxy-3-phenylpropyl)-1,4(S)-bis-(4-methoxyphenyl-2-azetidinone;
3(R)-(3(S)-hydroxy-3-phenylpropyl)-1,4(S)-bis-(4-methoxyphenyl-2-azetidinone;
4(S)-(4-hydroxyphenyl)-3(R)-(3(R)-hydroxy-3-phenylpropyl-1-(4-methoxyphenyl)-2-azetidinone;
4(S)-(4-hydroxyphenyl)-3(R)-(3(S)-hydroxy-3-phenylpropyl-1-(4-methoxyphenyl)-2-azetidinone;
rel 3(R)-[3(RS)-hydroxy-3-[4-methoxymethoxy)-phenyl]propyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone; and
1-(4-fluorophenyl)-3(R)-[3(R)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone;
4(S)-[4-(acetyloxy)phenyl]-3(R)-(3(R)-hydroxy-3-phenylpropyl)-1-(4-methoxyphenyl)-2-azetidinone;
4(S)-[4-(acetyloxy)phenyl]-3(R)-(3(S)-hydroxy-3-phenylpropyl)-1-(4-methoxyphenyl)-2-azetidinone;
1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4(S)-(phenylmethoxy)phenyl]-2-azetidinone;
3(R)-[3(R)-acetyloxy)-3-phenylpropyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
3(R)-[3(S)-acetyloxy)-3-phenylpropyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
3(R)-[3(R)-(acetyloxy)-3-(4-fluorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-fluorophenyl)-2-azetidinone;
3(R)-[3(S)-(acetyloxy)-3-(4-fluorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-fluorophenyl)-2-azetidinone;
3(R)-[3(R)-(acetyloxy)-3-(4-chlorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-chlorophenyl)-2-azetidinone;
3(R)-[3(S)-(acetyloxy)-3-(4-chlorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-chlorophenyl)-2-azetidinone; and
rel 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-3(1R)-(1(R)-hydroxy-3-phenylpropyl)-2-azetidinone.
8. A pharmaceutical composition for the treatment or prevention of athersclerosis, atherosclerosis or for the reduction of plasma cholesterol levels, comprising an effective amount of a compound of claim 1 7 in a pharmaceutically acceptable carrier.
9. A method of treating or preventing atherosclerosis or reducing plasma cholesterol levels comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 7.
10. A compound comprising 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-4-(hydroxyphenyl)-2-azetidinone or a pharmaceutically acceptable salt thereof.
11. A compound represented by the formula:
12. A pharmaceutical composition for the treatment or prevention of atherosclerosis, or for the reduction of plasma cholesterol levels, comprising an effective amount of a compound according to claims 10 or 11 in a pharmaceutically acceptable carrier.
13. A method of treating or preventing atherosclerosis or reducing plasma cholesterol levels comprising administering to a mammal in need of such treatment an effective amount of a compound according to claims 10 or 11.
US12797341 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents Expired - Lifetime USRE42461E1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10244093 true 1993-09-21 1993-09-21
US08257593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1994/010099 WO1995008532A1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US12797341 USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US09594996 USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12797341 USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09594996 Reissue USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
USRE42461E1 true USRE42461E1 (en) 2011-06-14

Family

ID=26799377

Family Applications (4)

Application Number Title Priority Date Filing Date
US08257593 Expired - Lifetime US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US12797341 Expired - Lifetime USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08617751 Expired - Lifetime US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US09594996 Expired - Lifetime USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08257593 Expired - Lifetime US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US08617751 Expired - Lifetime US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US09594996 Expired - Lifetime USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Country Status (14)

Country Link
US (4) US5631365A (en)
JP (1) JP2803908B2 (en)
KR (1) KR186853B1 (en)
CN (1) CN1050830C (en)
CA (1) CA2172149C (en)
DE (4) DE10399001I2 (en)
DK (1) DK0720599T3 (en)
EP (1) EP0720599B1 (en)
ES (1) ES2132432T3 (en)
FI (1) FI110321B (en)
LU (4) LU91050I2 (en)
NL (2) NL300132I2 (en)
RU (1) RU2138480C1 (en)
WO (1) WO1995008532A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093189A1 (en) 2012-12-10 2014-06-19 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5846966A (en) * 1993-09-21 1998-12-08 Schering Corporation Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
JPH10501811A (en) * 1994-06-20 1998-02-17 シェーリング コーポレイション Useful as hypocholesterolemic agents substituted azetidinone compound
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1997012053A1 (en) * 1995-09-27 1997-04-03 Schering Corporation Stereoselective microbial reduction process
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
EP0766962A3 (en) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Treatment of atherosclerosis
CA2235943C (en) * 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (en) * 1997-04-21 1999-06-11 Francois Trantoul Process for manufacturing a film unreproducible pattern by optical scanning for the protection of materials
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
EP1137634B1 (en) * 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
JP2002533409A (en) 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestrants for application to the cardiovascular
DK1140188T3 (en) 1998-12-23 2003-09-29 Searle Llc Combinations of ileal bile acid transport inhibitors, and cholesteryl esters tranferproteinhæmmere for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
CA2356607A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
CA2356515A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
DK1140184T3 (en) * 1998-12-23 2003-09-29 Searle Llc Combinations of cholesterylestertransferproteinhæmmere and nicotinic acid derivatives for cardiovascular indications
US6562860B1 (en) 1998-12-23 2003-05-13 G. D. Searle & Co. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
CN1338944A (en) 1998-12-23 2002-03-06 G.D.瑟尔有限公司 Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
JP3679715B2 (en) 1999-04-05 2005-08-03 シェーリング コーポレイションSchering Corporation 1- (4-fluorophenyl) -3 (r) - [3 (s) - hydroxy-3- (4-fluorophenyl) propyl)] - 4 (s) - (4-hydroxyphenyl) -2-azetidinone stereoselective microbial reduction for the preparation
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2003528830A (en) 2000-03-10 2003-09-30 ファルマシア・コーポレーション Method for producing tetrahydrobenzo Chie pin acids
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
WO2002036124A3 (en) * 2000-10-30 2003-02-13 Alan G Harris Treatment and method using loratadine and montelukast
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1593670B1 (en) * 2000-12-20 2007-08-08 Schering Corporation Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60129863T2 (en) 2000-12-20 2008-04-30 Schering Corp. Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic drug
KR20030061462A (en) 2000-12-21 2003-07-18 아벤티스 파마 도이칠란트 게엠베하 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
KR100820983B1 (en) * 2001-01-26 2004-03-26 쉐링 코포레이션 A pharmaceutical composition comprising substituted azetidinone compounds
KR100596257B1 (en) * 2001-01-26 2006-07-03 쉐링 코포레이션 A composition comprising sterol absorption inhibitor, and a composition and a therapeutic combinations comprising peroxisome proliferator-activated receptorPPAR activator and sterol absorption inhibitor
CA2438961C (en) * 2001-02-23 2010-02-16 Kotobuki Pharmaceutical Co., Ltd. Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
JP4145663B2 (en) 2001-03-28 2008-09-03 シェーリング コーポレイションSchering Corporation Enantioselective synthesis of azetidinone intermediate compound
DE60216275T2 (en) * 2001-05-25 2007-06-21 Schering Corp. Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP2005518347A (en) * 2001-11-02 2005-06-23 ジー.ディー. サール エルエルシー Apical sodium co-dependent bile acid transport (ASBT) and novel mono- and di-fluorinated benzothiepine compounds as inhibitors of taurocholate uptake
US20030181520A1 (en) * 2001-11-09 2003-09-25 Mitchell Glass Methods of reversing and preventing cardiovascular pathologies
US7094801B2 (en) * 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
WO2003053359A3 (en) 2001-12-19 2004-04-15 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
FR2833842B1 (en) 2001-12-21 2004-02-13 Aventis Pharma Sa Pharmaceutical compositions based derivatives of azetidine
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
EP1480689A1 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
DE10227508A1 (en) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Acid group-substituted Diphenylazetidinones, process for their production, medicaments containing these compounds and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
CA2493076A1 (en) 2002-07-26 2004-02-05 Merck Sharp & Dohme Limited Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
US6933292B2 (en) * 2002-07-30 2005-08-23 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
CN100439361C (en) 2003-03-07 2008-12-03 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP4589919B2 (en) * 2003-03-07 2010-12-01 シェーリング コーポレイションSchering Corporation For the treatment of hypercholesterolemia, substituted azetidinone compounds, these formulations and use
WO2004099132A3 (en) * 2003-05-05 2005-03-24 Ram Chander Aryan Process for the preparation of trans-isomers of diphenylazetidinone derivatives
EP1624871B1 (en) 2003-05-15 2009-07-15 Merck & Co., Inc. (a New Jersey corp.) Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
EP1651231A4 (en) * 2003-07-24 2009-04-01 Merck & Co Inc Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005009955A1 (en) * 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
WO2005042692A3 (en) * 2003-10-31 2005-09-09 Forbes Medi Tech Inc A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
DK1682499T3 (en) * 2003-11-10 2008-01-02 Microbia Inc 4-biarylyl-1-phenylazetidin-2-ones
EP1687287A1 (en) * 2003-11-24 2006-08-09 Hetero Drugs Limited A novel process for ezetimibe intermediate
US7871998B2 (en) * 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
EP1699760B1 (en) 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005069900B1 (en) * 2004-01-16 2006-08-03 Merck & Co Inc Npc1l1 (npc3) and methods of identifying ligands thereof
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
DE502005001841D1 (en) * 2004-05-21 2007-12-13 Sanofi Aventis Deutschland A process for the preparation of 1,4-diphenylazetidinone derivatives
CA2569124C (en) 2004-06-07 2013-04-23 Merck & Co., Inc. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006004903A3 (en) * 2004-06-28 2006-05-04 Atherogenics Inc 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006026273A3 (en) * 2004-08-25 2006-09-08 Merck & Co Inc Method of treating atherosclerosis, dyslipidemias and related conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
CA2578290A1 (en) * 2004-09-09 2006-03-16 Novartis Ag Combination of organic compounds
JP2008514718A (en) * 2004-09-29 2008-05-08 シェーリング コーポレイションSchering Corporation Combinations of substituents Azechidonon and cb1 antagonists
CA2589483C (en) 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
EP1834180A2 (en) * 2004-12-15 2007-09-19 Schering Corporation Functional assays for cholesterol absorption inhibitors
EP1865947A1 (en) 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
EP1893571A2 (en) 2005-05-06 2008-03-05 Microbia Inc. Process for production of 4-biphenylyazetidin-2-ones
WO2006122117A3 (en) * 2005-05-09 2007-01-18 Microbia Inc Organometal benzenephosphonate coupling agents
EP1885703A4 (en) * 2005-05-11 2009-09-02 Microbia Inc Processes for production of phenolic 4-biphenylylazetidin-2-ones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1896135A2 (en) * 2005-05-25 2008-03-12 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
CN101198338A (en) * 2005-06-15 2008-06-11 默克公司 Anti-hypercholesterolemic compounds
ES2337727T3 (en) * 2005-06-20 2010-04-28 Schering Corporation Piperidine derivatives useful as histamine H3 antagonists.
US8013150B2 (en) * 2005-06-22 2011-09-06 Msn Laboratories Ltd. Process for the preparation of ezetimibe
CN101243077A (en) * 2005-06-22 2008-08-13 阿斯利康(瑞典)有限公司 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
KR20080019709A (en) * 2005-06-22 2008-03-04 아스트라제네카 아베 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
KR20070063592A (en) 2005-09-08 2007-06-19 테바 파마슈티컬 인더스트리즈 리미티드 Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
JP4879991B2 (en) * 2005-10-05 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション Anti-hypercholesterolemia compound
KR20080059233A (en) 2005-10-21 2008-06-26 노파르티스 아게 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
DK1963260T3 (en) * 2005-12-20 2011-01-17 Richter Gedeon Nyrt A process for the preparation of ezetimibe and intermediates used therefore
JP2009521452A (en) * 2005-12-21 2009-06-04 シェーリング コーポレイションSchering Corporation Treatment of non-alcoholic fatty liver disease using the cholesterol-lowering agent and h3 receptor antagonists / inverse agonists
DE602006009845D1 (en) * 2005-12-22 2009-11-26 Medichem Sa A process for the preparation of intermediates for the preparation of ezetimibe
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
US7956182B2 (en) * 2006-02-16 2011-06-07 Kotobuki Pharmaceutical Co., Ltd. Process for preparing optically active alcohols
EP1986489A2 (en) * 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US20080032964A1 (en) * 2006-04-10 2008-02-07 Kansal Vinod K Process for the synthesis of azetidinone
JP2009538277A (en) * 2006-04-27 2009-11-05 アストラゼネカ アクチボラグ Diphenylazetidinone derivatives with cholesterol absorption inhibitory activity
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CN101494980A (en) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
EP1937636A1 (en) * 2006-08-29 2008-07-02 Teva Pharmaceutical Industries Ltd. Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl¨azetidin-2-one
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008033464A3 (en) * 2006-09-15 2008-05-15 Robert G Aslanian Azetidinone derivatives for the treatment of disorders of the lipid metabolism
CN101541805A (en) 2006-09-15 2009-09-23 先灵公司 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
WO2008033456A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
CA2663503A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
JP2010503672A (en) * 2006-09-15 2010-02-04 シェーリング コーポレイションSchering Corporation Spirocyclic Azetidinone Derivatives for treating lipid metabolism disorders, pain, diabetes mellitus, and other disorders
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN100564357C (en) 2006-10-20 2009-12-02 浙江天宇药业有限公司 Azacyclo butanone derivative and its synthesis process
EP1939174A1 (en) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
CN102285906B (en) 2007-01-24 2014-11-19 克尔克公司 Process for preparation of ezetimibe and derivatives thereof
WO2008096372A3 (en) * 2007-02-06 2010-06-24 Ind-Swift Laboratories Limited Process for preparing highly pure ezetimibe using novel intermediates
WO2008104875A1 (en) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
EP2133347A4 (en) 2007-03-06 2010-03-17 Teijin Pharma Ltd 1-biarylazetidinone derivatives
WO2008112166A3 (en) 2007-03-09 2008-10-30 Indigene Pharmaceuticals Inc Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2008130616A3 (en) * 2007-04-19 2008-12-18 Schering Corp Diaryl morpholines as cb1 modulators
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2010529148A (en) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド Reduction method for the ezetimibe production
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
EP2170847A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
KR20100051625A (en) * 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Substituted piperazines as cb1 antagonists
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
WO2009024889A3 (en) 2007-08-21 2009-07-09 Vinod Arora Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
WO2009027785A3 (en) * 2007-08-30 2009-09-17 Pfizer Products Inc. 1, 3-oxazole derivatives as cetp inhibitors
EP2217214B1 (en) * 2007-12-10 2017-07-19 ratiopharm GmbH Pharmaceutical formulation comprising ezetimibe
WO2009106021A1 (en) * 2008-02-25 2009-09-03 Zentiva, K.S. Intermediates for the preparation of (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4-fluorophenyl) -3-hydroxypropyl) ] -4- (4-hydroxyphenyl) -2-azetidinone
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
JP2011521992A (en) * 2008-06-06 2011-07-28 ニコックス エス エイ Atorvastatin 4- (nitroxy) a composition comprising a butyl ester and lipid lowering agent
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2329014B1 (en) 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2403848A1 (en) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmaceutical hypocholesterolemic compositions
EP2229938B9 (en) 2009-03-13 2012-04-25 Sanovel Ilac Sanayi ve Ticaret A.S. Ezetimibe compositions
EP2414326B1 (en) 2009-03-31 2017-12-20 Lupin Limited Intermediates in the preparation of 1,4-diphenyl azetidinone
WO2011002424A3 (en) 2009-07-02 2011-04-28 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation comprising ezetimibe and simvastatin
WO2011002422A3 (en) 2009-07-02 2011-04-28 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
CN101993403B (en) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 Azetidinone compound and medical applications thereof
ES2575560T3 (en) 2009-08-19 2016-06-29 Codexis, Inc. Ketoreductase polypeptides to prepare phenylephrine
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2372460B1 (en) 2010-07-09 2012-11-16 Moehs Ibérica S.L. New method for the preparation of ezetimibe.
CA2815749A1 (en) 2010-11-08 2012-05-18 Albireo Ab Ibat inhibitors for the treatment of liver diseases
EP2637646B1 (en) 2010-11-08 2016-05-11 Albireo AB A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
WO2012076030A1 (en) 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp Methods for treating lysosomal acid lipase deficiency
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
WO2012173504A3 (en) 2011-06-15 2013-02-21 Instytut Chemii Organicznej Polskiej Akademii Nauk Method for synthesis of the substituted azetidinones and intermediates for their synthesis
CN102675177A (en) * 2011-06-28 2012-09-19 常州制药厂有限公司 Preparation methods of blood fat lowering medicament and key intermediates of blood fat lowering medicament
CN102952055A (en) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 Preparation method of ezetimibe and its intermediate
CN103204795B (en) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 Preparing azetidinones one chiral compound
CN103570574B (en) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 One kind of ezetimibe ezetimibe synthesis and the intermediates used in the process
CN103102297A (en) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 Synthesis method of novel atorvastatin
CN103864708A (en) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 Preparation method of ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
US20160355473A1 (en) 2013-12-18 2016-12-08 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
CN103739537B (en) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
US20170252352A1 (en) 2014-05-30 2017-09-07 Pfizer Inc. Methods of use and combinations
CN104447474A (en) * 2014-11-11 2015-03-25 武汉武药科技有限公司 Synthetic method of ezetimibe isomer
CN104387308A (en) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 Method for preparing high-purity ezetimibe by controlling generation of EZ-zanOH impurity
CN104513187B (en) * 2015-01-09 2017-05-31 安润医药科技(苏州)有限公司 By synthetic methods and intermediates ezetimibe

Citations (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (en) 1970-09-23 1972-03-30
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
CA1173837A (en) 1981-03-09 1984-09-04 Theodore Goodson, Jr. 4-fluoroazetidinones
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
EP0199630A1 (en) 1985-04-10 1986-10-29 Merck & Co., Inc. Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicaments
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4659716A (en) 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1987004429A1 (en) 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
EP0264231A1 (en) 1986-10-17 1988-04-20 Taisho Pharmaceutical Co. Ltd Azetidinone derivatives
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4794108A (en) 1984-04-24 1988-12-27 Takeda Chemical Industries, Ltd. 1-carboxymethoxy acetidinones and their production
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co., Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
CA1262357A1 (en) 1984-08-03 1989-10-17 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
EP0337549A1 (en) 1988-04-11 1989-10-18 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
CA1267415A (en) 1983-02-02 1990-04-03 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
EP0365364A2 (en) 1988-10-20 1990-04-25 Taisho Pharmaceutical Co. Ltd 2-Azetidinone derivatives
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
EP0401705A2 (en) 1989-06-05 1990-12-12 E.R. Squibb & Sons, Inc. Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5030628A (en) 1988-12-19 1991-07-09 Scientifique N-aryl-azetidinones, their preparation process and their use as elastase inhibitors
EP0462667A2 (en) 1990-06-20 1991-12-27 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5099034A (en) 1989-06-30 1992-03-24 Shionogi & Co., Ltd. Phospholipase a2 inhibitor
CA2052973A1 (en) 1990-10-15 1992-04-16 Conrad P. Dorn Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5159025A (en) 1988-06-16 1992-10-27 Idemitsu Petrochemical Co., Ltd. Styrene-based copolymer and process for production thereof
CA2072215A1 (en) 1991-06-25 1992-12-26 Paul E. Finke New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
CA2114007A1 (en) 1991-07-23 1993-02-04 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
WO1994006784A1 (en) 1992-09-23 1994-03-31 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of acat
CA2152351A1 (en) 1992-12-23 1994-07-07 Harry R. Davis Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1994017036A1 (en) 1993-01-22 1994-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents
CA1331755C (en) 1983-03-28 1994-08-30 Marvin Joseph Miller Process for producing .beta.-lactam compounds
WO1994019351A1 (en) 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5350868A (en) 1991-09-27 1994-09-27 Ube Industries, Ltd. ω-hydroxy-(ω-3)-ketonitrile and method for preparing ω-hydroxyaliphatic acid
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
EP0720599A1 (en) 1993-09-21 1996-07-10 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688990A (en) 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5728827A (en) 1993-07-09 1998-03-17 Schering Corporation Process for the synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5767126A (en) 1991-06-18 1998-06-16 Marchbanks; Roger Michael Alzheimer's disease treatment with tacrine metabolites
US5817806A (en) 1994-03-26 1998-10-06 Glaxo Wellcome Spa Process for the preparation of cyclohexyl-azetidinones
US5847115A (en) 1992-11-13 1998-12-08 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5846966A (en) 1993-09-21 1998-12-08 Schering Corporation Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
US5856473A (en) 1995-11-02 1999-01-05 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US5925668A (en) 1997-01-22 1999-07-20 Asta Medica Aktiengesellschaft Thioctic metabolites and methods of use thereof
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US6372756B1 (en) 1998-02-20 2002-04-16 Avmax, Inc. Epimorphian compound and its use
US6455572B1 (en) 2000-04-07 2002-09-24 Pfizer Inc. Estrogen agonist/antagonist metabolites
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (en) 1970-09-23 1972-03-30
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
CA1173837A (en) 1981-03-09 1984-09-04 Theodore Goodson, Jr. 4-fluoroazetidinones
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
CA1213596A (en) 1982-06-23 1986-11-04 Tatao Luo 1-alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)- phenyl-azet-2-ones as plant growth regulators
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4479900A (en) 1982-06-23 1984-10-30 Chevron Research Company 1-Carbalkoxyalkyl-3-aryloxy-4-(2'-carboxyphenyl)-azetidin-2-ones
CA1267415A (en) 1983-02-02 1990-04-03 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
CA1331755C (en) 1983-03-28 1994-08-30 Marvin Joseph Miller Process for producing .beta.-lactam compounds
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
CA1253146A (en) 1983-10-03 1989-04-25 William A. Slusarchyk Azetidinones
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4659716A (en) 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
US4794108A (en) 1984-04-24 1988-12-27 Takeda Chemical Industries, Ltd. 1-carboxymethoxy acetidinones and their production
CA1262357A1 (en) 1984-08-03 1989-10-17 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
EP0199630A1 (en) 1985-04-10 1986-10-29 Merck & Co., Inc. Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicaments
CA1286304C (en) 1985-04-10 1991-07-16 Peter L. Barker Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1987004429A1 (en) 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
EP0264231A1 (en) 1986-10-17 1988-04-20 Taisho Pharmaceutical Co. Ltd Azetidinone derivatives
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co., Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
EP0337549A1 (en) 1988-04-11 1989-10-18 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5159025A (en) 1988-06-16 1992-10-27 Idemitsu Petrochemical Co., Ltd. Styrene-based copolymer and process for production thereof
EP0365364A2 (en) 1988-10-20 1990-04-25 Taisho Pharmaceutical Co. Ltd 2-Azetidinone derivatives
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
CA2004355A1 (en) 1988-12-05 1990-06-05 Michael P. Kirkup Process for intermediate compounds for preparing penems and carbapenems
US5030628A (en) 1988-12-19 1991-07-09 Scientifique N-aryl-azetidinones, their preparation process and their use as elastase inhibitors
EP0401705A2 (en) 1989-06-05 1990-12-12 E.R. Squibb & Sons, Inc. Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease
US5099034A (en) 1989-06-30 1992-03-24 Shionogi & Co., Ltd. Phospholipase a2 inhibitor
EP0415487A2 (en) 1989-08-31 1991-03-06 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
CA2024267A1 (en) 1989-08-31 1991-03-01 Shu S. Yang Beta-lactams as anticholesterolemic agents
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0462667A2 (en) 1990-06-20 1991-12-27 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0481671A1 (en) 1990-10-15 1992-04-22 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
CA2052973A1 (en) 1990-10-15 1992-04-16 Conrad P. Dorn Substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
US5767126A (en) 1991-06-18 1998-06-16 Marchbanks; Roger Michael Alzheimer's disease treatment with tacrine metabolites
CA2072215A1 (en) 1991-06-25 1992-12-26 Paul E. Finke New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5306817A (en) 1991-07-23 1994-04-26 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
WO1993002048A1 (en) 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
CA2114007A1 (en) 1991-07-23 1993-02-04 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5350868A (en) 1991-09-27 1994-09-27 Ube Industries, Ltd. ω-hydroxy-(ω-3)-ketonitrile and method for preparing ω-hydroxyaliphatic acid
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
WO1994006784A1 (en) 1992-09-23 1994-03-31 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of acat
US5847115A (en) 1992-11-13 1998-12-08 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5661145A (en) 1992-12-23 1997-08-26 Schering Corporation Combination of a cholesterol biosynthesis inhibitor and a β-lactam cholesterol absorption inhibitor
WO1994014433A1 (en) 1992-12-23 1994-07-07 Schering Corporation COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A β-LACTAM CHOLESTEROL ABSORPTION INHIBITOR
CA2152351A1 (en) 1992-12-23 1994-07-07 Harry R. Davis Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor
JPH08505141A (en) 1992-12-23 1996-06-04 シェリング・コーポレーション The combination of cholesterol biosynthesis inhibitors and β- lactam cholesterol absorption inhibitor
US5698548A (en) 1993-01-21 1997-12-16 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2154257A1 (en) 1993-01-21 1994-08-04 Sundeep Dugar Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1994017036A1 (en) 1993-01-22 1994-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents
WO1994019351A1 (en) 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
US5728827A (en) 1993-07-09 1998-03-17 Schering Corporation Process for the synthesis of azetidinones
US5846966A (en) 1993-09-21 1998-12-08 Schering Corporation Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
CA2172149C (en) 1993-09-21 2000-11-28 Stuart B. Rosenblum Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5767115A (en) 1993-09-21 1998-06-16 Schering-Plough Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0720599A1 (en) 1993-09-21 1996-07-10 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5688990A (en) 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5817806A (en) 1994-03-26 1998-10-06 Glaxo Wellcome Spa Process for the preparation of cyclohexyl-azetidinones
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5744467A (en) 1994-11-18 1998-04-28 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5856473A (en) 1995-11-02 1999-01-05 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5925668A (en) 1997-01-22 1999-07-20 Asta Medica Aktiengesellschaft Thioctic metabolites and methods of use thereof
US6372756B1 (en) 1998-02-20 2002-04-16 Avmax, Inc. Epimorphian compound and its use
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
US6455572B1 (en) 2000-04-07 2002-09-24 Pfizer Inc. Estrogen agonist/antagonist metabolites
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Non-Patent Citations (515)

* Cited by examiner, † Cited by third party
Title
"Heart disease" Statistics http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.html#heartdiesease © 2010.
Abel et al., Cortisol Metabolism by Human Liver in vitro-I Metabolite identification and Inter-Individual Variability, J. Steroid. Biochem. Molec. Biol. 43(7):713-719 (1992).
Abel et al., Cortisol Metabolism by Human Liver in vitro-IV. Metabolism of 9 alpha-fluorocortisol by Human Liver Microsomes and Cytosol., J. Steroid. Biochem. Molec. Biol. 46(6):833-839 (1993).
Abel et al., Cortisol Metabolism by Human Liver in vitro-IV. Metabolism of 9 α-fluorocortisol by Human Liver Microsomes and Cytosol., J. Steroid. Biochem. Molec. Biol. 46(6):833-839 (1993).
Affidavit of A. Louise McLean, dated Apr. 9, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Antonio M. Gotta Jr., M.D., D.Phil. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Dr. John Clader (Inventor) re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jun. 26, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Gary Thiessen re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SSR/06-242; SOR/2008-211, dated Jun. 30, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Glenn Ikeda, dated Apr. 13, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of John D. Sutherland, dated Apr. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Leslie Z. Benet re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Mark Wentland re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Neal Castagnoli, Ph.D. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations. SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08).
Affidavit of Sonia Atwell re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SSR/98-66; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08).
Ajmera et al., Synthesis and Biological Activity of 5-Fluoro-2',3'-dideoxy-3'-Fluorouridine and Its 5'-Phosphate, J. Med. Chem. 27(1):11-14 (1984).
Ajmera et al., Synthesis and Biological Activity of 5-Fluoro-2′,3′-dideoxy-3′-Fluorouridine and Its 5′-Phosphate, J. Med. Chem. 27(1):11-14 (1984).
Allain et al., Enzymatic Determination of Total Serum Cholesterol, Clinical Chemical 20:470-475 (1974).
Altmann et al., Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption, Science 303:1201-1204 (2004).
Altschul et al., Influence of Nicotinic Acid on Serum Cholesterol in Man, Arch Biochem, 54(2):558-559 (1955).
Amended Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: May 3, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Amended Answer to Complaint, Separate Defenses, Amended Counterclaim and Jury Demand against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Mar. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
American Heritage Dictionary of the English language, 2nd College ed., Houghton Mifflin Co.-"appy as remedy" (1985).
American Heritage Dictionary of the English language, 2nd College ed., Houghton Mifflin Co.—"appy as remedy" (1985).
Angelin et al., Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition, Eur. J. Clin. Invest. 16:391-396 (1986).
Anitschkow and Chalatow, On Experimental Cholesterin Steatosis and Its Significance in the Origin of Some Pathological Processes, Arteriosclerosis 3(2):178-182 (1983).
Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Answer to Complaint with Jury Demand , Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Jul. 28, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC).
Answer to Complaint, Counterclaim against all plaintiffs by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Corporate Disclosure Statement)(Walsh, Liza) (Entered: May 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Answer to Complaint, Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for ihe District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals, Inc. USA by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Answer to Counterclaim by MSP Singapore Company LLC, Schering Corporation.(Halper, Jason) (Entered: Apr. 7, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Answer to Counterclaim of Glenmark Pharmaceuticals, Inc. USA. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Answer to Counterclaim of Glenmark Pharmaceuticals, Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Arnerican Heart Association/American Stroke Association Report Dec. 2009, "Facts: Breaking Our Hearts: Still America's No. 1 Killer," formerly accessible at http://www.americanheart.org/presenter.jhdml?identifierequal3049018 (cited as document C32 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).
Augelli-Szafran et al., Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel alpha-ketoamides as hypocholesterolemic agents, J. Med. Chem. 36(20):2943-2949 (1993).
Augelli-Szafran et al., Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel α-ketoamides as hypocholesterolemic agents, J. Med. Chem. 36(20):2943-2949 (1993).
Austel and Kutter, Quant. Struct. Activity Relationships of Drugs, John G. Toplissm (ed.), Academic Press, pp. 437-496 (1983).
B. Ram et al., 1990, "Potential hypolipidemic agents:Part V†-Synthesis biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates‡" Indian Journal of Chemistry 29B:1134-1137.
Bannai et al., Synthesis of Chemically Stable Prostacyclin Analogs, Tetrahedron 39(22):3807-3819 (1983).
Barnard et al., The Effect of Fluorine Substitution on the Physicochemical Properties and the Analgesic Activity of Paracetamol, J. Pharm. Pharmacol. 45(8):736-744 (1993).
Bass et al., Effect of Ring Fluorination of Epinephrine on Its Cardiovascular Adrenoceptor Activities, Eur. J. Pharmacol. 187(1):87-95 (1990).
Baxter, A., 1992, "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo," The Journal of Biological Chemistry 267:11705-11708.
Baxter, Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in vivo, Journal of Biological Chemistry 267:11705-11708 (1992).
Bergstrom and Shum, Synthesis and Characterization of a New Fluorine Substituted Nonionic Dinucleoside Phosphonate Analogue, P-Deoxy-P-(difluoromethyl)thymidyly1(3′-> 5′)thymidine, J. Org. Chem. 53:3953-3958 (1988).
Bergstrom and Shum, Synthesis and Characterization of a New Fluorine Substituted Nonionic Dinucleoside Phosphonate Analogue, P-Deoxy-P-(difluoromethyl)thymidyly1(3'-> 5')thymidine, J. Org. Chem. 53:3953-3958 (1988).
Bergstrom et al., 3',3'-Difluoro-3'-Deoxythymidine:Comparison of Anti-HIV Activity to 3'-Fluoro-3'-Deoxythymidine, J. Med. Chem. 35(18):3369-3372 (1992).
Bergstrom et al., 3′,3′-Difluoro-3′-Deoxythymidine:Comparison of Anti-HIV Activity to 3′-Fluoro-3′-Deoxythymidine, J. Med. Chem. 35(18):3369-3372 (1992).
Bergstrom et al., Fluorine Substituted Analogs of Nucleosides and Nucleotides, Nucleos, Nucleot. 6(1 & 2):53-63 (1987).
Bey et al., Further Studies on the Inhibition of Monoamine Synthesis by Monofluoromethyldopa, Br. J. Pharmacol, 70(4):571-576(1980).
Black et al., Modulation of Carcinogenicity in 1,2, 3, 4-Tetrahydro-7,12-Dimethylbenz[a] Anthracene (THDMBA) by Fluorine Substitution: Crystal Structures of the 5- and 6- Fluoro Regioisomers, Carcinogenesis 13(8):1337-1343 (1992).
Blackburn et al., Isopolar vs isosteric Phosphonate Analogues of Nucleotides, Nucleos. Nucleot. 4(1 & 2):165-167 (1985).
Blackburn, Overview: The Seven Countries Study in Brief, http://www.epi.umn.edu/research/7countries/overview/shtm, downloaded on Aug. 10, 2010.
Blankenhorn and Hodis, Treating serum lipid abnormalities in high-priority patients, Postgrad. Med., 89(1):81-96 (1991).
Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (Abstract only).
Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (full copy) (cited in abstract form as document C52 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).
Braun and Galle, A simple stereoselective synthesis of cholestrol absorption inhibitor (--)- SCH 48461, Synthesis 7:819-820 (1996).
Bravo et al., Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoromuscarines, J. Med. Chem. 35(17):3102-3110 (1992).
Brief in Opposition re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Rule 56.1 Responsive Statement of Material Facts, # 2 Suh Declaration, # 3 Suh Declaration Exhibits (Redacted), # 4 Proposed Order, # 5 Certification of Service)(Halper, Jason) (Entered: Jul. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Brief in Opposition re Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Proposed Order, # 2 Certification of Service)(Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Brief in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Local Rule 56.1 Statement of Facts, # 2 Proposed Order, # 3 Certification of Service)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Brief in Opposition to Defendants' Opening Markman Brief filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Supplemental Krause Declaration, # 2 Supp. Krause Declaration, Exs. R-V, # 3 Supp. Krause Declaration, Exs. W-Y, # 4 Certification of Service)(Halper, Jason) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Brief in Response to Defendant's Opening Markman Brief filed by MSP Singapore Company LLC, Schering Corporation (Redacted) (Attachments: # 1 Supplemental Declaration of James Suh, # 2 Supp. Suh Declaration, Exhibit 38, # 3 Supp. Suh Declaration, Exhibit 39, # 4 Supp. Suh Declaration, Exhibit 40, # 5 Supp. Suh Declaration, Exhibit 41 (Redacted)), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Brief In Response To Plaintiffs' Proposed Claim Interpretations filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Certification of Service)(Walsh, Liza) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Brief—Mylan's Responsive Claim Construction Brief filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 40 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Brockman et al., Metabolism and Chemotherapeutic Activity of 9-beta-D-Arabinofuranosyl-2-Fluoroadenine against Murine Leukemia L1210 and Evidence for Its Phosphorylation by Deoxycytidine Kinase, Cancer Res. 40(10):3610-3615 (1980).
Brockman et al., Metabolism and Chemotherapeutic Activity of 9-β-D-Arabinofuranosyl-2-Fluoroadenine against Murine Leukemia L1210 and Evidence for Its Phosphorylation by Deoxycytidine Kinase, Cancer Res. 40(10):3610-3615 (1980).
Brodbeck et al., Fluorinated Aldehydes and Ketones Acting as Quasi-Substrate Inhibitors of Acetylcholinesterase, Biochim. Biophys. Acta. 567(2):357-369 (1979).
Brooks and Wiley, Evolution as Entropy. Towards a Unified Theory of Biology, D.L. Hull (editor) Second Edition (University of Chicago Press), Table of Contents (1968).
Brown and Bowden, New Twists on an Old Theme, Chem. Ind. 5:143-147 (1993).
Brown, Review of Clinical Studies of Fenofibrate in Combination with Currently Approved Lipid-Lowering Drugs, Cardiology 76(1):45-54 (1989).
Buffa and Peters, The in vivo Formation of Citrate Induced by Fluoroacetate and Its Significance, J. Physiol. 110(3-4):488-500 (1950).
Bugrim, "Early Prediction of Drug Metabolism and Toxicity: Systems Biology Approach and Modeling," Drug Discovery Today 9(3):127-135 (2004).
Buhler et al. Metabolism and Tumorigenicity of 7-, 8-,9-, and 10-Fluorobenzo(a) Pyrenes, Cancer Res. 42(11):4779-4783 (1982).
Burger, Progress in Drug Research. Fortschritte der Arneimittelforschung Progres des rescherches pharmaceutiques, Prog. Drug. Res. 37:287-371 (1991).
Burnett and Davis, "Chapter 6. Recent Advances in the Science and Treatment of Atherosclerosis," Annual Reports In Med. Chem., vol. 36, pp. 57-66 (Greenlee, Ed.), Academic Press (2001).
Burnett at al., 2-Azetidinones as Inhibitors of Cholesterol Absorption, J. Med. Chem. 37(12):1733-1736 (1994).
Burnett et al., Synthesis of Iodinated Biochemical Tools Related to the 2-Azetidinone Class of Cholesterol Absorption Inhibitors, Biorg. & Med. Chem. Letters 12:311-314 (2002).
Burnett, Asymmetric synthesis and absolute stereochemistry of cholesterol absorption inhibitor, SCH 48461, Tet. Letters 35(40):7339-7342 (1994).
Burnett, beta-Lactam Cholesterol absorption inhibitors, Curr. Med. Chem. 11:1873-1887 (2004).
Burnett, β-Lactam Cholesterol absorption inhibitors, Curr. Med. Chem. 11:1873-1887 (2004).
Burrier et al., Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster, Biochemical Pharmacology 47:1545-1551 (1994).
Burrier et al., The Effect of Acyl CoA: Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine. J. Pharmacol. Exp. Ther. 372(1): 156-163 (1995).
Burrier et al., The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine, The Journal of Pharmacology and Experimental Therapeutics 272:156-163 (1994).
Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", Biochemical Pharmacology 47:1545-1551.
Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", The Journal of Pharmacology and Experimental Therapeutics 272:156-163.
Bush and Mahesh Metabolism of 11-Oxygenated Steroids. 2. 2-Methyl Steroids, Biochem. J. 71(4):718-742 (1959).
Bush and Mahesh, Metabolism of 11-Oxygenated Steroids. 3. Some 1-Dehydro and 9 alpha-fluoro Steroids, Biochem. J. 93(2):236-255 (1964).
Bush and Mahesh, Metabolism of 11-Oxygenated Steroids. 3. Some 1-Dehydro and 9 α-fluoro Steroids, Biochem. J. 93(2):236-255 (1964).
Butler and Gray, The Metabolism of Betamethasone, J. Endocrinol. 46(3):379-390 (1970).
C. Allain et al., 1974, "Enzymatic Determination of Total Serum Cholesterol" Clinical Chemical, 20:470-475.
Campbell et al., beta-Lactamase Activity of Purified and Partially Characterized Human Renal Dipeptidase, J. Biol. Chem. 259(23):14586-14590 (1984).
Campbell et al., β-Lactamase Activity of Purified and Partially Characterized Human Renal Dipeptidase, J. Biol. Chem. 259(23):14586-14590 (1984).
Carpenter et al., Pharmacokinetics of Inhaled Anesthetics in Humans: Measurements During and After the Simultaneous Administration of Enflurane, Halothane, Isoflurane, Methoxyflurane, and Nitrous Oxide, Anesth. Analg. 65(6):575-582 (1986).
Carrell et al., Fluorocitrate Inhibition of Aconitase: Relative Configuration of Inhibitory Isomer by X-Ray Crystallography Science 170(965):1412-1414 (1970).
Cates, Calculation of drug solubilities by pharmacy students, Am. J. Pharm. Ed., 45:11-13 (1981).
Certification in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Declaration of James Suh filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exibits 1-4, # 2 Exhibits 5-16, # 3 Exhibits 17, # 4 Exhibit 18 (Part 1), # 5 Exhibit 18 (Part 2) # 6 Exhibits 19-21, # 7 Exhibit 22, # 8 Exhibits 23-25, # 9 Exhibit 26 (Part 1), # 10 Exhibit 26 (Part 2), # 11 Exhibit 26 (Part 3), #12 Exhibit 26 (Part 4), # 13 Exhibits 27-29, # 14 Exhibits 30-32, # 15 Exhibit 33, # 16 Exhibit 34, # 17 Exhibits 35-40, # 18 Exhibits 41-46, # 19 Exhibit 47 (Part 1), # 20 Exhibit 47 (Part 2), # 21 Exhibits 48-52, # 22 Exhibit 53 (Part 1), # 23 Exhibit 53 (Part 2), #24 Exhibit 53 (Part 3), # 25 Exhibits 54-60, # 26 Exhibit 61 (Part 1), # 27 Exhibit 61 (Part 2), # 28 Exhibits 62-63, # 29 Exhibit 64, # 30 Exhibits 65-69)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)
Chen et al., Asymmetric Synthesis of Substituted 2-Azaspiro[3.5]nonan-1-ones: An Enantioselective Synthesis of the Cholesterol Absorption Inhibitor (+)-SCH 54016, J. Org. Chem. 61(23):8341-8343 (1996).
Chiba et al., Oxidative Metabolism of Omeprazole in Human Liver Microsomes: Cosegregation with S-Mephenytoin 4'- Hydroxylation, J. Pharmacol. Exp. Ther. 266(1):52-59 (1993).
Chiba et al., Oxidative Metabolism of Omeprazole in Human Liver Microsomes: Cosegregation with S-Mephenytoin 4′- Hydroxylation, J. Pharmacol. Exp. Ther. 266(1):52-59 (1993).
Clader et al., 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus, J. Med. Chem. 39:3684-3693 (1996).
Clader et al., Substituted (1,2-Diarylethyl)amide Acy-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity, Journal of Medicinal Chemistry 38:1600-1607 (1995).
Clader, Ezetimibe and other Azetidinone Cholesterol Absorption Inhibitors, Curr. Topics in Med. Chem. 5(3):243-256 (2005).
Clader, Ezetimibe: Chemistry-Driven Drug Discovery in the Absence of a Defined Molecular Target Schering-Plough Research Institute Visio Presentation (slides) (2005).
Clader, J.W. et al., 1995, "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" Journal of Medicinal Chemistry 38:1600-1607.
Clader, The Discovery of Ezetimibe: A View from Outside the Receptor, J. Med. Chem. 47(1):1-9 (2004).
Claudi et al., Synthesis and Dopamine Receptor Affinities of 2-(4-Fluoro-3-Hydroxyphenyl) Ethylamine and N-Substituted Derivatives, J. Med. Chem. 33(9):2408-2412 (1990).
Complaint against Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Statement 7.1 disclosure# 2 Civil Cover Sheet # 3 Summons Glenmark, USA# 4 Summons Glenmark Ltd.)(mn, ) (Entered: Mar. 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Complaint against Impax Laboratories, Inc., filed by Schering Corporation, MSP Singapore Company, LLC. (Attachments: # 1 EXH A, # 2 EXH B, # 3 EXH C, # 4 Civil Cover Sheet, # 5 Summons)(dr, ) (Entered: Aug. 24, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04270-JLL-CCC).
Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Cover letter)(kd) (Entered: Dec. 18, 2009), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK).
Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: #1 Summons1, # 2 Summons2, # 3 Civil Cover Sheet)(Id) (Entered: Dec. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 16, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC).
Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 29, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK).
Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Civil Cover Sheet)(dr) (Entered: Mar. 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A to Complaint, # 2 Exhibit B to Complaint, # 3 Exhibit C to Complaint, # 4 Summonsl, # 5 Summons2, # 6 Civil Cover Sheet)(Id, ) (Entered: Sep. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04473-JLL-CCC).
Complaint; summons issued against Impax Laboratories, Inc., Filed by Schering Corporation, MSP Singapore Company LLC. (slh) (Filed on Aug. 20, 2010) (Entered: Aug. 23, 2010), U.S. District Court for the Northern District of California (Civil Action No. 3:10-cv-03719-JSW).
Consent Judgment on Counterclaim, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).
Consent Judgment. Signed by Judge Jose L. Linares on May 10, 2010. (DD) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Corrected Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals, Inc. USA Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Cross Examination Transcript of Gary Thiessen, dated Sep. 15, 2009, Federal Court of Canada (Court File No. T-1610-08).
Cross-Examination transcript of John W. Clader, dated Dec. 9, 2009, Federal Court of Canada (Court File No. T-1610-08).
Cross-Examination transcript of Mark Wentland, dated Dec. 4, 2009, Federal Court of Canada (Court File No. T-1610-08).
Curtis et al., Double-blind, placebo-controlled cross-over trial of cholestyramine an bezafibrate in the treatment of monogenic familial hypercholesterolaemia (FH), Atherosclerosis 68:271 (1987).
D. Roger Hlingworth, 1988, "An Overview of Lipid-Lower Drugs" Drugs 36:63:71.
Davidson and Eastham, Acute Liver Necrosis Following Overdose of Paracetamol, Br. Med. J. 2(5512):497-499 (1966).
Davis et al., Species Differences in Hepatic Glutathione. Depletion, Covalent Binding and Hepatic Necrosis After Acetaminophen Life Sci., 14(11):2099-2109 (1974).
Davis et al., The hypercholesterolemic activity of the potent cholesterol absorption inhibitor SCH 58235 alone and in combination with HMG CoA reductase inhibitors, XII Int'l Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 62 (1995).
Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3·Hydroxy-3·Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, Metabolism 50(10):1234-1241 (2001).
Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated Jan. 27, 1997 from file history of U.S. Appl. No. 08/449,978.
Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated May 8, 1996 from file history of U.S. Appl. No. 08/257,593.
DeBernardis et al., Conformationally Defined Adrenergic Agents. 1. Design and Synthesis of Novel alpha2 Selective Adrenergic Agents: Electrostatic Repulsion Based Conformational Prototypes, J. Med. Chem. 28(10):1398-1404 (1985).
DeBernardis et al., Conformationally Defined Adrenergic Agents. 1. Design and Synthesis of Novel α2 Selective Adrenergic Agents: Electrostatic Repulsion Based Conformational Prototypes, J. Med. Chem. 28(10):1398-1404 (1985).
Declaration of Antonio M. Gotto, dated Sep. 29, 2010, U.S. District Court cm the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Declaration of Gerald S. Brenner, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES).
Declaration of James Suh in Support of Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Declaration of Srilakshmi M. Ravi (Supplemental) by Mylan Pharmaceuticals Inc., (Attachments: # 1 Exhibit 36 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 2 Exhibit 37 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 3 Exhibit 38 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 4 Exhibit 39 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Declaration of Srilakshmi M. Ravi, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Defendant Impax Laboratories, Inc.'s Answer, Affirmative Defenses, Counterclaims and Jury Demand, dated Sep. 24, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)).
Defendant Mylan Pharmaceuticals Inc.'s Amended Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6 (redacted for Mylan confidential information), dated Sep. 9, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Defendant Mylan Pharmaceuticals Inc.'s Answer To Plaintiffs' Complaint, Separate Defenses and Counterclaims, dated Jul. 28, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-03085 (JLL-ES)).
Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-3), dated Jul. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
deGennes et al., Long-term (over 5 years) treatment of primary hyperlipidemia by fenofibrate alone or with cholestyramine, Treatment of Hyperlipoproteinemia, (Carlson and Olsson, eds.), Raven Press, NY, pp. 175-180 (1984).
Dembowski and Davidson, Statin and Ezetimibe Combination Therapy in Cardiovascular Disease. Curr. Opin. Endocrinol. Diabetes Obes. 16(2):183-188 (2009).
Deposition of Antonio M. Gotto, Jr., M.D., D. Phil., dated Nov. 23, 2009, Federal Court of Canada (Court File No. T-1610-08).
Deposition of Neal Castagnoli, Ph.D., dated Nov. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).
Deposition Transcript of Adriano Afonso, dated Oct. 21, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Anita Magatti, dated Jan. 7, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Cecil B. Pickett, dated Nov. 14, 2008. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Dorothy Auth, dated Jan. 9, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Dr. John Sutherland (Cross-examination), dated Oct. 20, 2009, Federal Court of Canada (Cout File No. T.1610-08).
Deposition Transcript of Dr. Wayne Vaccaro, dated Jun. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Duane Burnett, dated Sep. 25, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition 'Transcript of Harry Davis, dated Oct. 14, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of James Nelson, dated Oct. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of James Nelson, dated Oct. 30, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of John Clader, Ph.D, dated Dec. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Kevin Alton, dated Sep. 9, 2008, U.S. District Court for the District of New Jersey (Civil Action no. 07-cv-1334 {JLL/ES)).
Deposition Transcript of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).
Deposition Transcript of Margaret Van Heek, dated Sep. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Nathan Yumibe, dated May 9, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Stuart B. Rosenblum, dated Dec. 4, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Stuart B. Rosenblum, dated Dec. 5, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Stuart Rosenbaum, dated Feb. 10, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Deposition Transcript of Sundeep Dugar, Ph.D., dated May 2, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Development of new stereoisomeric drugs, May 1, 1992, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm122883.htm, downloaded Aug. 10, 2010.
Di Giulio, et al., Encapsulation of Ampicillin in Reverse-Phase Evaporation Liposomes: A Direct Evaluation by Derivative Spectrophotometry, Int. J. Pharm. 74:183-188 (1991).
Dodd et al., Metabolism and Pharmacokinetics of Selected Halon Replacement Candidates, Toxicol. Lett. 68(1-2):37-47 (1993).
Doherty et al., Design and Synthesis of Potent, Selective, and Orally Active Fluorine-Containing Renin Inhibitors, J. Med. Chem. 35(1):2-14 (1992).
Dolle et al., ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Sulfoximine and 3-Hydroxy-beta-Lactam Containing Analogues of Citric Acid as Potential Tight-Binding Inhibitors, J. Med. Chem. 35(26):4875-4884 (1992).
Dolle et al., ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Sulfoximine and 3-Hydroxy-β-Lactam Containing Analogues of Citric Acid as Potential Tight-Binding Inhibitors, J. Med. Chem. 35(26):4875-4884 (1992).
Dollery et al., (eds) Therapeutic Drugs, vol. 1, Churchill Livingstone, Edinburgh (1991).
Dorland's Illustrated Medical Dictionary, 30th Ed., W.B. Saunders & Co., Canada, p. 1513 (2003)-"prodrug".
Dorland's Illustrated Medical Dictionary, 30th Ed., W.B. Saunders & Co., Canada, p. 1513 (2003)—"prodrug".
Drazen et al., Cholesterol Lowering and Ezetimibe, N. Eng. J. Med. 358(14):1507-1508 (2008).
Drug Information, Baycol Information, Center for Drug Evaluation and Research, 2001, http://www.fda.gov/cder/drug/infopagelbaycol/default.htm, downloaded Apr. 15, 2009.
Dugar et al., Amides of Piperidine, Morpholine and Piperazine Substituted 1-Phenylethylamines: Inhibitors of AcylCoA:cholesterol Acyltransferase (ACAT) Activity in vitro and in vivo, Bioorg. Med. Chem., 3(9):1231-1236 (1995).
Dugar et al., Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461, Bioorg. Med. Chem. Lett. 5(24)2947-2952 (1995).
Dugar et al., Metabolism and structure activity data based drug design; discovery of (-) SCH 53079 an analog of the potent cholesterol absorption inhibitor (-) SCH 48461, Bioorg. Med. Chem. Lett. 6(11):1271-1271 (1996).
Dugar et al., N-Oleayl-l,2,3,4-Tetrahydroisoquinolines as Conformationally Restricted Inhibitors of Acyl-CoA:Cholesterol Acyl Transferase (ACAT), Bioorg. Med. Chem. Lett., 3(4):571-576 (1993).
Dugar et al., Substituted 2-Azaspiro[5.3]nonan-1-ones as Potent Cholesterol Absorption Inhibitors: Defining a Binding Conformation for SCH 48461, J. Med. Chem. 38(25):4875-4877 (1995).
DuJovne et al., Probucol with colestipol in the teatment of hypercholesteolemia, Ann. Intern. Med. 100:477-482 (1984).
Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (Abstract only).
Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (full copy) (cited in abstract form as document C106 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).
Durst et al., Metallation of N-Substituted beta-Lactams, A Method for the Introduction of 3-Substituents into beta-Lactams, Canadian Journal of Chemistry, 50:3196-3201 (1971).
Durst et al., Metallation of N-Substituted β-Lactams, A Method for the Introduction of 3-Substituents into β-Lactams, Canadian Journal of Chemistry, 50:3196-3201 (1971).
Duschinsky et al., The Synthesis of 5-Fluoropyrimidines, J. Am. Chem. Soc. 79:4559-4560 (1957).
Dysken et al., Fluphenazine Pharmacokinetics and Therapeutic Response, Psychooharmacology 73:205-210 (1981).
East et al., Combination drug therapy for treatment of patients with familial combined hyperlipidemia resulting in combined hypertriglyceridemia and hypercholesterolemia, Arteriosclerosis 6:544A (1986).
Eger et al., Is Enfiurane Hepatotoxic? Anesth. Analg. 65(1)21-30 (1986).
El Masry, Studies in Detoxication. 69. The metabolism of alkylbenzenes: n-propylbenzene and n-butylbenzene with further observations of ethylbenzene, Biochem J. 64(1):50-56 (1956).
Elliott, The Role of Fluorine in the Development of Central Nervous System Agents in Biomedicinal Aspects of Fluorine Chemistry (R. Fuller and Y. Kobayashi, eds.), Elsevier Biomedical Press, New York, pp. 55-74, (1982).
Erlenmeye et al., Justus Liebigs Annalen der Chemie, Liepzig, C.F. Wintersche Verladshandluna, pp. 51-123 (1907), vol. 356.
Expert Report of Christopher A. Vellturo. Ph.D., dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of Clayton Heathcock, Ph.D., dated Feb. 25, 2009, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of Dr. Ronald Hines, dated Feb. 27, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of F. Peter Guengerich, dated Apr. 16, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of Paul Ortiz de Montellano, Ph.D., dated Mar. 2, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of Richard Bruce van Breernen, Ph.D., dated Mar. 2, 2009, U.S District Court for the District of New Jersey (Civil Action No. 07-cv-1337 (JLL/ES)).
Expert Report of Ronald G. Brisbois, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of Stephen G. Kunin, Esq. , dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/Es)).
Expert Report of W. Virgil Brown, M.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Expert Report of William R. Roush, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Filler, Organofluorine Chemicals and their Industrial Applications (Banks, R. E, ed.), Ellis Horwood Ltd. Publishers, Chichester, Ch. 6 Fluorine-containing Drugs (1979).
Final Pretrial Order, U.S. District Court for the District of New Jersey (redacted for Glenmark confidential information and personal information of witnesses), signed Mar. 11, 2010 (Civil Action No. 07-cv-1334 (JLL/ES)).
First Amended Answer to Complaint by Glenmark Pharmaceuticals Ltd. (Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES).
First Amended Answer to Complaint by Glenmark Pharmaceuticals, Inc.USA.(Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Frey and Frey, Urinary 6 β-Hydroxyprednisolone Excretion Indicates Enhanced Prednisolone Catabolism, J. Lab. Clin. Med. 101(4):593-604 (1983).
Fried and Sabo, 9α-Fluoro Derivatives of Cortisone and Hydrocortisone, J. Am. Chem. Soc. 76:1455-1456 (1954).
Fried et al., 10,10-Difluoro-13-Dehydroprostacyclin: A Chemically and Metabolically Stabilized Potent Prostacyclin, J. Med. Chem. 23(3):234-237 (1980).
Fried et al., Synthesis and Properties of 7,7-Difluoro Derivatives of the 2,6-Dioxa[3.1.1] bicycloheptane Ring System Present in Thromboxane A2, J. Am. Chem. Soc. 106:3871-3872 (1984).
G. George et al., 1985 "3-(T-Hydroxyethyl)-2-Azetidinones From 3-Hdyroxy-butyrates and N-Arylaldimines" Tetrahedron Letters, vol. 26, No. 33 pp. 3903-3906.
Garcia-Calvo et al., The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1), Proc. Natl. Acad. Sci. USA 102(23):8132-8137 (2005).
Gazi et al., Effect of Ezetimibe in Patients Who Cannot Tolerate Statins or Cannot Get to the Low Density Lipoprotein Cholesterol Target Despite Taking a Statin, Curr. Med. Res. Opin. 23(9):2183-92 (2007).
Generic Pharmaceutical Association. Facts at a Glance. http://www.gphaonline.org/about-gpha/about-generics/facts © 2010.
Georg and Gill, Stereo—and Enantio-controlled synthesis of chiral intermediates for the total synthesis of thienaycin and related β-Lactam antibiotics from 3-hydroxybutyrates, J. Chem. Soc., Chem. Comm. pp. 1433-1435 (1985).
Georg et al., 3-(1′-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines, Tetrahedron Letters 26(33):3903-3906 (1985).
Georg et al., 3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines, Tetrahedron Letters 26(33):3903-3906 (1985).
Georg et al., An Impoved Mehod For The Stereoselective Synthesis Of B-Lactams From Carboxylic Acids And Imines, Tet. Lett. 32(5):581-584(1991).
Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Amended Responses to Plaintiffs' Interrogatories (Nos. 1-17), dated Mar. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 1, dated May 11, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 4, dated Nov. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Goldstein and Brown, Cholesterol: A Century of Research. HHMI Bulletin, vol. 16, No. 3, Sep. 2003.
Gootz et al., "Pharmacokinetic Studies in Animals of a New Parenteral Penem CP-65,207 and its Oral Prodrug Ester," J. Antibiot. 43(4):422-432 (1990).
Gotto, Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease, Circulation 114:1310-1314 (2006).
Grundy et al., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation 110(2):227-239 (2004).
Grundy et al., Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in Heterozygous familial hypercholesterolemia, Ann. Intern. Med., 103:339-343 (1985).
Guengerich and MacDonald, Chemical Mechanism of Catalysis by Cytochromes P-450: A Unified View, Acc. Chem. Res. 17:9-16 (1984).
H. Otto et al., 1983, "Darstellung und Stereochemic von 3-(α-Hydroxybenzyl)-1,4-diphenyl-azetidononen", Liebigs Ann. Chem. 1152-1161.
Halloran et al., An Examination of the Importance of 24-Hydroxylation to the Function of Vitamin D During Early Development, Endocrinology 108(6):2067-2071 (1981).
Hansch and Leo, Cluster Analysis and the Design of Congener Sets, in Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley & Sons, NY, Ch. 6, 48-54 (1979).
Harris and Anders, Metabolism of the Hydrochlorofluorocarbon 1,2-Dichloro-1,1-Difluoroethane, Chem. Res. Toxicol. 4(2):180-186 (1991).
Harris et al., Pentahaloethane-Based Chlorofluorocarbon Substitutes and Halothane: Correlation of In Vivo Hepatic Protein Trifluoroacetylation and Urinary Trifluoroacetic Acid Excretion with Calculated Enthalpies of Activation, Chem. Res. Toxicol. 5(5):720-725 (1992).
Harris et al., Tissue Acylation by the Chlorofluorocarbon Substitute 2,2-Dichloro-1,1,1-Trifluoroethane, Proc. Natl. Acad. Sci. USA 88(4):1407-1410 (1991).
Harrison et al., Metabolic Defluorination of 5-Fluoro-Amodiaquine in the Rat, Br. J. Clin. Pharmacol. 34:148P-149P (1992).
Hart and Ha, The Ester Enoiate-Imine Condensation Route to β-Lactams, Chem. Rev. 89(7):1447-1465 (1989).
Hart et al., 1985 "An Enantioselective Approach to Carhapenen Antibodies: Formal Synthesis of (+)-Thienamycin" Tetrahedron Letters, vol. 26, No. 45 pp. 5493-5496.
Hart et al., An Enantioselective Approach to Carbapenen Antibodies: Formal Synthesis of (+)-Thienamycin, Tetrahedron Letters, 26(45):5493-5496 (1985).
Harwood, H. James, 1993, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818;tiqueside)1 " Journal of Lipid Research 34:377-395.
Harwood, Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin beta-tigogenin cellobioside (CP-88818; liqueside), Journal of Lipid Research 34:377-395 (1993).
Harwood, Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818; liqueside), Journal of Lipid Research 34:377-395 (1993).
Hearing Transcript before the Honorable Jose L. Linares (Markman Hearing), dated Jul. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Hecht et al., Comparative Mutagenicity, Tumor-Initiating Activity, Carcinogenicity, and In Vitro Metabolisrn of Fluorinated 5-Methylchrysenes, J. Natl. Cancer Inst. 63(3):855-861 (1979).
Hecht et al., Reduction of Tumorigenicity and of Dihydrodiol Formation by Fluorine Substitution in the Angular Rings of Dibenzo(a,i) Pyrene, Cancer Res. 41(11 Pt. 1):4341-4345 (1981).
Heidelberger et al., Fluorinated Pyrimidines, a New Class of Tumour-Inhibitory Compounds, Nature 179(4561):663-666 (1957).
Heidelberger, The Nucleotides of Fluorinated Pyrimidines and Their Biological Activities, in Carbon-Fluorine Compounds: Chemistry, Biochemistry and Biological Activities, (K. Elliot, ed.), Associated Scientific Publishers, Amsterdam, pp. 125-140 (1972).
Herper, Behind Zetia's curtain, http://www.forbes.com/2002/10/31/cx, downloaded Apr. 29, 2010.
High Blood Cholesterol: What you need to know, http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm—downloaded Aug. 10, 2010.
Hitt et al., Metabolism of Isoflurane in Fischer 344 Rats and Man, Anesthesiology 40(1):62-67(1974).
Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) (full copy) (cited in abstract form as document C143 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,3741).
Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) Abstract only.
Hodgkins and Megarity, A Study of Benzyl Free Radical and Substituted Benzyl Free Radicals, J. Amer. Chem. Soc. 87(23):5322-5326 (1965).
Hoeg et al., The Effects of Mevinolin and Neomycin Alone and in Combination on Plasma Lipid and Lipoprotein Concentrations in Type II Hyperlipoproteinemia, Atherosclerosis 60:209-214 (1986).
Hoeg, Combination Drug Therapy, in Drug Treatment of Hyperlipidemia, Ch. 10, (Rifkind, Ed.), Marcel Dekker, Inc., pp. 215-231 (1991).
Hoekman et al., Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Add delta-Lactones, J. Agric, Food Chem. 30:920-924 (1982).
Hoekman et al., Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Add δ-Lactones, J. Agric, Food Chem. 30:920-924 (1982).
Horie et al., Hypolipidemic effects of NB-598 in dogs, Atherosclerosis 88:183-192 (1991).
Horie, M. et al. 1991, "Hypolipidemic effects of NB-598 in dogs" Atherosclerosis 88:183-192.
Huberman and Slaga, Mutagenicity and Tumor-Initiating Activity of Fluorinated Derivatives of 7,12-Dimethylbenz(a)Anthracene, Cancer Res. 39(2 Pt. 1):411-414 (1979).
Hughes and Saunders, Enzymatic Rupture of a C-F Bond, Chem. Ind. (London) 1265 (1954).
Humphrey and Smith, Role of metabolism ad pharmacokinetic studies in the discovery of new drugs—present and future perspectives, Xenobiotica 22(7):743-755 (1992).
Husain et al., Fluoride Elimination from Substrates in Hydroxylation Reactions Catalyzed by p-Hydroxybenzoate Hydroxylase, J. Biol. Chem. 255(9):4189-4197 (1980).
Illingworth and Bacon, Hypolipidemic Effects of HMG-CoA Reductase Inhibitors in Patients with Hypercholesterolemia, Am. J. Cardiol. 60(12):33g-42g (1987).
Illingworth et al., Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia, Lancet 1(8215):296-298 (1981).
Illingworth et al., Long-Term Experience with HMG-CoA Reductase Inhibitors in the Therapy of Hypercholesterolemia, Atherosclerosis Revs. 18:161-187 (1988).
Illingworth, An Overview of Lipid-Lower Drugs, Drugs 36:63:71 (1988).
Illingworth, Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia, Ann. Intern. Med. 101:598-604 (1984).
Intelligence.360, Global Pharmaceutical Perspectives, Making sense of the year—and what lies ahead—in a time of unprecedented challenge and opportunity, 2006.
International Search Report dated Dec. 8, 1994 in PCT/US94/10099.
Jackevicius, C. A. et al., "Long-term Trends in Use of and Expenditures for Cardiovascular Medications in Canada," Canadian Medical Association Journal, 181(1-2):E19-E28, Jul. 7, 2009 (cited as document C156 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).
Jamali, Stereochemically Pure Drugs—An Overview, Drug Stereochemistry, in Analytical Methods and Pharmacology. Ch. 14, pp. 375-384 (1993).
Jerina et al., Carcinogenicity of Benzo[a]Pyrene, in Drug Design and Adverse Reactions (II. Bundgaard, P. Juul, and H. Kafod, eds.), Academic Press, New York, pp. 261-275 (1977).
Jeu and Cheng, Pharmacology and Therapeutics of Ezetimibe (SCH 58235), a Cholesterol-Absorption Inhibitor, Clin. Ther. 25(9):2352-2387 (2003).
Joint Claim Construction and PreHearing Statement, dated Jul. 23, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-0v-06383 (JLL/ES)).
Jones et al. Biotransformation and Hepato-Renal Function in Volunteers After Exposure to Desflurane (1-653), Br. J. Anaesth. 64(4):482-487 (1990).
Joseph L. Witztum, M.D., 1989, "CUrrent Approaches to Drug Therapy for the Hyercholesterolemic Patient" Circulation 80:1101-1114.
Kane et al., Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen, New Engl. J. Med. 304(5):251-258 (1981).
Kastelein et al., Simvastatin with or without ezetimibe in Familial Hypercholesterolemia, New Eng. J. Med. 358(14):1431-43 (2008).
Kastelein, Statin Therapy with Ezetimibe or Niacin in High-Risk Patients, New Eng. J. Med., 361:2180-2183 (2009).
Kaufman, The enzymic conversion of 4-fluorophenylalanine to tyrosine, Biochim, Biophys. Acta 51:619-621 (1961).
Kawase et al., Mechanism of Autoxidation of 5,7-Dihydroxytryptamine: Effect of Fluorine Substitution at Positions 4 and/or 6, Chem. Pharm, Bull 38(11):2939-2946 (1990).
Kenna et al., Metabolic Basis for a Drug Hypersensitivity: Antibodies in Sera From Patients With Halothane Hepatitis Recognize Liver Neoantigens that Contain the Trifluoroacetyl Group Derived from Halothane, J. Pharmacol. Exp. Ther. 245(3):1103-1109 (1988).
Kimura et al., Structure-activity relationship of a series of phenylureas linked to 4-phenylimidazole. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity. 2., J. Med. Chem. 36(11):1641-1653 (1993).
Kimura et al., Structure-Activity Relationship of N-[2-(Dimethylamino)-6-[3-(5-Methy1-4- Phenyl-1H-Imidazol-1-yl)Propoxy]Phenyl]-N'-Pentylurea and Analogues. Novel Potent Inhibitors of Acyl-CoA: Cholesterol O-Acyltransferase with Antiatherosclerotic Activity, J. Med. Chem. 36(11):1630-1640 (1993).
Kirk et al., Syntheses and adrenergic agonist poperies of ring-fluorinated isoproterenols, J. Med. Chem. 25(6):680-684 (1982).
Kirk et al., Synthesis and adrenergic activity of ring-fluorinated phenylepherines, J. Med. Chem. 29(10):1982-1988 (1986).
Kirkup et al., (-)-SCH 57939: Synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor, Bioorg. Med. Chem. Lett. 6(17):2069-2072 (1996).
Kitteringham et al., Conjugation of dinitrofluorobenzene to plasma proteins in vivo in the rat, Drug Metab. Dispos. 20(5):625-631 (1992).
Kobayashi and Taguchi, Fluorinated Vitamin D3 Analogs Syntheses and Biological Activites, in Biomedical Aspects of Fluorine Chemistry (R. Filler and Y. Kobayashi, eds.), Associated Scientific Publishers, Amsterdam, pp, 33 (1982).
Koblin et al., I-653 Resists Degradation in Rats, Anesth. Analg. 67(6):534-538 (1988).
Kollonitsch et al., Selective Inhibitors of biosynthesis of Aminergic Neurotransmitters, Nature 274(5674):906-908 (1978).
Kong et al., Comparisons of Anti-Human Immunodeficiency Virus Activites, Cellular Transport, and Plasma and Intracellular Pharmacokinetics of 3′-Fluoro-3′-Deoxythymidine and 3′-Azido-3′-Deoxythymidine, Antimicrob. Agents Chernother, 36(4):808-818 (1992).
Kripalani et al., Metabolism of Triamcinolone Acetonide-21-Phosphate in Dogs, Monkeys, and Rats, J. Pharm. Sci. 64(8):1351-1359 (1975).
Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989;45:28-33.
Kropp et al., Meabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I Antimicrob. Agents Chemother. 22(1):62-70 (1982).
Kuo et al., Effects of Combined Probucol-Colestipol Treatment for Familial Hypercholesterolemia and Coronary Artery Disease, Am. J. Cardiol. 57:43H-48H (1986).
Landsberg, Can Entropy and "Order" Increase Together? Physics Letters 102A(4):171-173 (1984).
Landsberg, Is Equilibrium Always an Entropy Maximum? J. Stat. Physics 35(1/2):159-169 (1984).
Lees et al., Therapy of Hypercholesterolemia with Mevinolin and Other Lipid-Lowering Drugs, Arteriosclerosis 6:544 (1986).
Lehninger et al., Principles of Biochemistry, Second Edition (Worth Publishers, NY), Table of Contents (1993).
Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp,, and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to §505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act. dated Nov. 5, 2009.
Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp., and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to §505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act, dated May 25, 2010.
Letter from Defendants In Response to Plaintiffs' Aug. 1 Suppl Briefing On Claim Construction. (Ruiz, Hector) (Entered: Aug. 7, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Defendants in Response to Plaintiffs' Aug. 8, 2008 Letter On Claim Construction Issues. (Ruiz, Hector) (Entered: Aug. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. regarding Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13.. (Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Impax Laboratories, Inc. to MSP Singapore Co. LLC, Merck & Co., Inc. and Schering Corporation. re: Paragraph IV Patent Certification Notice for U.S. Patent Nos. RE37,712 and 5,846,966, dated Jul. 9, 2010.
Letter from Liza M. Walsh to the Honorable Jose L. Linares. (Attachments: # 1 Brief in Support of Proposed Claim Interpretations# 2 Declaration of Agnes Antonian # 3 Text of Proposed Order # 4 Certificate of Service)(Walsh, Liza) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief. (Attachments: # 1 Brief# 2 Proposed Order# 'Certification of Service# 4 Krause Declaration, Ex. A# 5 Krause Declaration, Ex. B# 6 Krause Declaration, Ex. C Part 1# 7 Krause Declaration, Ex. C Part 2# 8 Krause Declaration, Ex. C Part 3# 9 Krause Declaration, Ex. D Part 1# 10 Krause Declaration, Ex. D Part 2# 11 Krause Declaration, Ex. D Part 3# 12 Krause Declaration, Ex. D Part 4# 13 Krause Declaration, Ex. E Part 1# 14 Krause Declaration, Ex. E Part 2# 15 Krause Declaration, Ex. E Part 3# 16 Krause Declaration, Ex. E Part 4# 17 Krause Declaration, Ex. E Part 5# 18 Krause Declaration, Ex. E Part 6# 19 Krause Declaration, Exs. F-G# 20 Krause Declaration, Exs. H-O# 21 Krause Declaration, Exs. P-Q)(Halper, Jason) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Plaintiffs in Reply to Glenmark's Aug. 6, 2008 Letter re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 8, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Plaintiffs in Response to Defendants' Notice of Supplemental Authority re Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue). (Halper, Jason) (Entered: Jan. 14, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Plaintiffs regarding July 29 Markman Hearing re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 1, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Letter from Plaintiffs Schering Corporation and MSP Singapore Company LLC to Judge Esther Salas seeking Modification of Proposed Claim Constructions Provided inJoint Claim Construction and Prehearing Statement (Proposed Order attached), dated Sep. 14, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Letter from Teva Pharmaceuticals USA, Inc, to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 078724 Concerning Ezetimibe Tablets, 10 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721 and 7,612,058, dated Jul. 20, 2010.
Letter from Teva Pharmaceuticals USA, Inc. to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 200909 Concerning Ezetimibe/Simvastatin Tablets, 10 mg/80 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721, dated Feb. 19, 2010.
Li et al., Catechol Formation of Fluoro—and Bromo-Substituted Estradiols by Hamster Liver Microsomes. Evidence for Dehalogenation, Mol. Pharmacol. 27(5):559-565 (1985).
Liehr, 2-Fluoroestradiol, Separation of Estrogenicity from Carcinogenicity, Mol. Pharmacol. 23(2)278-281 (1983).
Lien, Structure-Absorption-Distribution Relationships: Significance for Drug Design, in Drug Design, vol. V, (Ariëns, Ed.) Academic Press, NY, pp. 81-132 (1975).
Lloyd-Jones et al., Heart Disease and Stroke Statistics—2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, pp. e22-e181 (Jan. 27, 2009) (downloaded from circ.ahajournals.org on Apr 14, 2009).
Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Jaime N. Delgado and William A. Remers, Eds., 9th Ed., J.B. Lippincott Company, pp. 45-127 (1991).
Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Robert F. Doerge, Ed., 8th Ed., J.B. Lippincott Company, pp. 55-127 (1982).
Low and Castagnoli, Drug Biotransformations, in Burger's Medicinal Chemistry, 4th Ed., Part I, The Basis of Medicinal Chemistry, (Wolff, ed.), John Wiley & Sons, NY, pp. 108-226 (1980).
Low and Castagnoli, Metabolic Changes of Drugs and Related Organic Compounds, in Wilson and Gisvolds Textbook of Organic Medicinal and Pharmaceutical Chemistry, 9th Ed., Ch. 3, (Delgado and Remers, Eds.), pp. 45-127 (1991).
M. Hoekman et al., 1982, "Synthesis of Homologues of 4.5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Acid-Lactones", J. Agric. Food Chem., 30:920-924.
Mabuchi et al., Reduction of serum cholesterol in heterozygous patients with familial hyperchalesterolemia, New Eng. J. Med, 308:609-613 (1983).
Malloy et al., Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia, Ann. Intern. Med., 107:616-623 (1987).
Mann et al., Probucol in patients resistant to the lipid lowering effects of cholestyramine, Lancet Feb. 21;1(8217):450-451 (1981).
Mann, Modern Methods for the Introduction of Fluorine into Organic Molecules: An Approach to Compounds with Altered Chemical and Biological Activities, Chem. Soc. Rev. 16:381-436 (1987).
Manuel et al., Burden of cardiovascular disease in Canada, Can J. Cardiol. 19(9):997-1004.
March, Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Fourth Edition (Wiley 1992) University of Michigan, Table of Contents.
Masood et al., 2′-Fluoro-2,3′-Dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2′,3′-Dideoxyadenosine, Mol. Pharmacol, 37(4):590-596 (1990).
Matthes et al., Phosphorylation, Anti-HIV Activity and Cytotoxicity of 3′-Fluorothymidine, Biochem. Biophys. Res. Commun. 153(2):825-831 (1988).
Mauro and Tuckerman, Ezetimibe for Management of Hypercholesterolemia, Ann. of Phormacother. 37:839-848 (2003).
Mayrhofer et al., Simple Prep. of 3-Benzylidene-2-azetilidinones, Synthesis 247-8 (1980).
Mazze et al., Inorganic Fluoride Nephrotoxicity: Prolonged Enflurane and Halothane Anesthesia in Volunteers, Anesthesiology 46(4):265-271 (1977).
Mazze et al., Methoxyflurane Metabolism and Renal Dysfunction: Clinical Correlation in Man, Anesthesiology 35(3):247-252 (1971).
Mazze et al., Renal Effects and Metabolism of Isoflurane in Man, Anesthesiology 40(6):536-542 (1974).
McCarthy et al., 4′,5′-Unsaturated 5′-Fluoroadenosine Nucleosides: Potent Mechanism-Based Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase, J. Am. Chem. Soc. 111:1127-1128 (1989).
McCarthy, New Approaches to Atherosclerosis: An Overview, Med. Res. Rev. 13(2):139-159 (1993).
McGill et al., Natural History of Human Atherosclerotic Lesions, Atherosclerosis and its Origin, (Sandler and Bourne, eds.), pp. 39-65 (1963).
McKittrick et al., Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorg. & Med. Chem Lett. 6(16):1947-1950 (1996).
McKittrick et al., Synthesis of C3 Heteroatom-Substituted Azetidinones that display potent cholesterol absorption inihibitory activity, J. Med. Chem. 41(5):752-759 (1998).
Memorandum of Fact and Law of the Respondent NovoPharm Limited ("TEVA"), dated Mar. 29, 2010, Federal Court of Canada (Court File No. T-1610-08).
Merck Manual of Diagnosis & Therapy, 25th Ed., Berkow (ed.), Merck & Co., Inc., at p. 2430.—"pharmacokinetics" (1987).
Merriam-Webster's New Collegiate Dictionary, 8th ed., Merriam-Webster, Inc.—"administering" (1981).
Michalek et al., Pharmacokinetics of TCDD in veterans of Operation Ranch Hand; 10-year-follow-up, Journal of Toxicology and Environmental Health 52(6):557-558 (1997).
Miller and Miller, The Carcinogenicity of Fluoro Derivatives of 10-Methyl-1,2-Benzanthracene. I. 3- and 4′-Monofluoro Derivatives, Cancer Res. 20:133-137 (1960).
Minagawa et al., Identification and Quantification of 6 β-Hydroxydexamethasone as a Major Urinary Metabolite of Dexamethasone in Man, Steroids 47(2-3):175-188 (1986).
Molgaard et al., Long-term Efficacy and Safety of Simvastatin Alone and in Combination Therapy in Treatment of Hypercholesterolaemia, Atherosclerosis 91:S21-S28 (1991).
Montgomery et al., Synthesis and Biological Evaluation of 2-Fluoro-8-Azaadenosine and Related Compounds, J. Med. Chem. 26(10):1483-1489 (1983).
Morgan et al., Oxidative Dehalogenation of 2-Fluoro-17 α-Ethynyloestradiol in vivo. A Distal Structure-Metabolism Relationship of 17 α-Ethynylation, Biochem. Pharmacol. 44(9):1717-1724 (1992).
Morgan et al., The Metabolism of 2- and 4-Fluoro-17 β-Oestradiol in the Rat and its Implications for Oestrogen Carcinogenesis, Biochem. Pharmacol. 43(5):985-993 (1992).
Morinelli et al., Difluorothromboxane A2 and Stereoisomers: Stable Derivatives of Thromboxane A2 with Differential Effects on Platelets and Blood Vessels, Proc. Natl. Acad. Sci. U.S.A. 86(14):5600-5604 (1989).
Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Statement of Undisputed Material Facts, # 2 Confidential Memorandum of Law [Redacted], # 3 Confidential Declaration of Robert L. Jacobson [Redacted], # 4 Confidential Exhibits A-E [Redacted], # 5 Confidential Exhibits F-K [Redacted], # 6 Proposed Order, # 7 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD,). (Entered: Jul. 1, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Brief in Support of Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13, # 2 Text of Proposed Order, # 3 Certificate of Service)(Halper, Jason) (Entered: Apr. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) by Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd. (Attachments: #1 Statement of Material Facts Not in Dispute, # 2 Memorandum of Law In Support of Summary Judgment, # 3 Declaration of George Hykal, # 4 Exhibits A through B to George Hykal Declaration, # 5 Exhibits C through E to George Hykal Declaration, # 6 Exhibits F through H to George Hykal Declaration, # 7 Proposed Order, # 8 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD, ). (Entered: Jul. 8, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Motion to Dismiss for Failure to State a Claim Upon Which Relief May Be Granted and/or for Lack of Subject Matter Jurisdiction by Mylan Inc. (Attachments: #1 Brief in support of Mylan, Inc.'s Motion to Dismiss, # 2 Declaration of Andrew Kozusko in support of Mylan, Inc.'s Motion to Dismiss, # 3 Text of Proposed Order, # 4 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Murphy et al., Some Aspects of the Metabolism and Disposition of Betamethasone, Acta. Endocrinol. 45:498-508 (1964).
Murray-Rust, Intermolecular Interactions of the C-F Bond: The Crystallographic Environment of Fluorinated Carboxylic Acids and Related Structures, J. Am. Chem. Soc. 105:3206-3214 (1993).
Mylan's Opening Claim Construction Brief (Redacted), dated Sep. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Nagabhushan, T. L., Kandasamy, D., Tsai, H., Turner, W. N. & Miller, G. H. (1980). Novel class of chloramphenicol analogs with activity against chloramphenicol-resistant and chloramphenicol-susceptible organisms. In Current Chemotherapy and Infectious Disease, vol. 1, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 1979 (Nelson, J. D. & Grassi, C, Eds), pp. 442-443. American Society for Microbiology, Washington, DC.
Napoli et al., 1 α-hydroxy-25-fluorovitamin D3: a potent analogue of 1 α,25-dihydroxyvitamin D3, Biochemistry 17(12):2387-2392 (1978).
Napoli et al., 1-Fluorovitamin D3, a vitamin D3 analogue more active on bone-calcium mobilization than on intestinal-calcium transport, Biochemistry 18(9):1641-1646 (1979).
Negishi et al., Palladium-Catalyzed Acylation of Oganozincs and Other Organometalics as a Convenien Route to Ketones,Tetrahedron Lett. 24(47):5181-5184 (1983).
Nelson et al., Does Ammonia Hydrogen Bond? Science 238(4834): 1670-1674 (1987).
Nikkari et al., The hyperlipidemic hamster as an atherosclerosis model, Artery 18(6)285-290 (1991).
Nobuki et al., Stereoselective syntheses of beta-lactam derivatives by ultrasound promoted Reformatskii reaction, Chemical Abstracts No. 106:17 (1977) Abstract 138174y.
Nobuki et al., Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction, Chemical Abstracts No. 106:17 (1977) Abstract 138174y.
Nobuki, O. et al. "Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction" Chemical Abstracts No. 106, vol. 17, Apr. 27, 1977 abstract 138174y.
Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re MOTION for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) (Attachments: # 1 Appendix A)(Lessler, Jay) (Entered: Jan. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Notice of Voluntary Dismissal by MSP Singapore Company LLC, Schering Corporation (Attachments: # 1, Attachment Exhibit 1)(Simmerman, Frank) (Entered: Apr. 15, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK).
Notice of Voluntary Dismissal by MSP Singapore Company, LLC, Schering Corporation (Attachments: # 1 Exhibit, Exhibit One)(Simmerman, Frank) (Entered: Aug. 19, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK).
Oguni et al., Stereoselective Synthesis of β-Lactam Derivatives by Ultrasound Promoted Reformatskii Reaction, Chem. Abstracts No. 17, vol. 106:138174y (1987).
Opinion. Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Opinion. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD,) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Order granting Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting). Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Order granting Plaintiff's appl. For claims construction.. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD, ) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Order Reinstating re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals, Inc. USA, Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. Signed by Judge Jose L. Linares on Apr. 9, 2010. (DD, ) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Order Vacating re Order granting on Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue), Order on denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Apr. 19, 2010 Opinion. Signed by Judge Jose L. Linares on May 10, 2010. (DD, ) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Order withdrawing Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); withdrawing Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting); Signed by Judge Jose L. Linares on Mar. 30, 2010. (DD, ) (Entered: Mar. 31, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Ortiz de Montellano, ed., Cytochrome P-450. Structure, Mechanism, and Biochemistry, Ch. 7, Part 3.5, Heteroaton Oxidation and Dealkylation, Plenum Press (1986).
Otto et al., Darstellung und Stereochemie von 3-α-Hydroxybenzyl)-1,4-diphenyl-2-azetidononen, Liebigs Ann. Chem., vol. 1983, issue 7, pp. 1152-1161 (Aug. 15, 1983) (cited as document C16 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341).
Otto et al., Stereochemistry of dehydration and halogenation of alphaR* and alphaS* isomeric 3-(alpha-hydroyxbenzy1-1-4-dipheny1=2-azetidinones, Chemical Abstracts 19:99 (1983) Abstract 18083h.
Otto et al., Stereochemistry of dehydration and halogenation of αR* and αS* isomeric 3-(α-hydroxybenzyl)-1,4-diphenyl=2-azetidinones, Chemical Abstracts No. 19, vol. 99, Nov. 7, 1983 abstract 158083h.
Otto et al., Stereochemistry of dehydration and halogenation of αR* and αS* isomeric 3-(α-hydroyxbenzy1-1-4-dipheny1=2-azetidinones, Chemical Abstracts 19:99 (1983) Abstract 18083h.
Packard et al., Combined drug therapy for familial hypercholesterolemia, Artery 7(4):281-289 (1980).
Panfil et al., Synthesis of alpha-Lactams from a,alpha-Unsaturated Sugar delta-Lactones, Heterocycles 24:1009-1617(1986).
Panfil et al., Synthesis of α-Lactams from a,α-Unsaturated Sugar δ-Lactones, Heterocycles 24:1009-1617(1986).
Pantil. I. et al., 1986, "Synthesis of β-Lactams from α, β-Unsaturated Sugar δ-Lactones" Heterocycles 34:1609-1617.
Park and Kitteringham, Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications, Drug Metab. Reviews 26(3):605-643 (1994).
Patani and LaVoie, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 96(8):3147-3176 (1996).
Peters et al., Biochemistry of Fluoroacetate Poisoning: The Isolation and Some Properties of the Fluoroticarboxylic Acid Inhibitor of Citrate Metabolism, Proc. Roy. Soc. B140:497-507 (1952).
Peters, Some Metabolic Aspects of Fluoroacetate Especially Related to Fluorocitrate, in Carbon Fluorine Compounds: Chemistry, Biochemistry & Biological Activies, A Ciba Foundation Symposium, (Elsevier Excerpta Medica North-Holland), Associated Scientific Publishers, Amsterdam, london, New York, pp. 55-76 (1972).
Physician's Desk Reference, 46th Ed., pp. 1538, 1559-1560 (1992).
Pinedo and Petes, Fluorouracil: Biochemistry and Pharmacology, J. Clin. Oncol. 6(10):1653-1664 (1988).
Plaintiffs' Answer to Impax Laboratories, Inc.'s Counterclaims, dated Oct. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)).
Plaintiffs' Answer to Teva Pharmaceuticals USA, Inc.'s Counterclaims, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).
Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Plaintiffs' Response and Objections to Defendant Mylan Pharmaceuticals Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-11), dated Jul. 30, 2010, U.S. District Court for the District of new Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Plaintiffs' Responses to Glenmark's Second Set of Interrogatories (Nos. 17-21), dated Sep. 25, 2008, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Pohl et al., Neoantigens associated with halothane hepatitis, Drug Metab. Rev. 20(2-4):203-217 (1989).
Poston and Foreyt, Scientific and Legal Issues Fenfluramine/Dexfenfluramine Litigation, Tex. Med. 96(2):48-56 (2000).
Pretrial Memorandum by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
R. Mayrhofer et al. 1980. "Simple Preparation of 3-Benzylidene-2-azetilidinones" Synthesis, 247-248.
Ram et al., Potential hypolipidemic agents:Part V†-Synthesis biological activity of new ethyl 4-(2-oxazetidin-4-yl)phenoxyalkanoatest‡, Indian Journal of Chemistry 29B:1134-1137 (1990).
Rebuttal Expert Report of Clayton Heathcock, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Rebuttal Expert Report of Jesse David, dated May 8, 2009. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Rebuttal Expert Report of Paul Ortiz de Montellano, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Rebuttal Expert Report of Ronald N. Hines, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Regårdh et al., Plasma Levels and β-Blocking Effect of Hydroxymetoprolol—Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5):471-479 (1979) (Abstract only).
Regårdh et al., Plasma Levels and β-Blocking Effect of Hydroxymetoprolol—Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5)471-479 (1979) (full copy) (cited in abstract from as document C235 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).
Reifenrath et al., Synthesis and Biological Activity of Fluoroalkylamine Derivatives of Narcotic Analgesics, J. Med. Chem. 23(9):985-990 (1980).
Rekker and Mannhold, Calculation of Drug Lipophilicity—The Hydrophobic Fragmental Constant Approach (Jointly by VCH Verlagsgesellschaft, Weinhehn (Federal Republic of Germany) and VCH Publishers Inc., New York (USA)), Table of Contents (1992).
Reply Affidavit of John D. Sutherland, dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).
Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Amended Reply Brief filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Revised Declaration of Jay P. Lessler, # 2 Lttr. to Judge Linares Encl. Amended Reply and Revised Decl.)(Walsh, Liza) (Entered: Aug. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. To Suppl. Stmn. of Disputed Facts (Redacted), # 2 Decl. of Jay Lessler, # 3 Exhibit A pp. 1-29, # 4 Exhibit A pp. 30-59, # 3 : Exhibit A pp. 60-89, # 6 Exhibit A pp. 90-112, # 7 Exhibit B, # D, Exhibit C)(Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Reply Brief to Opposition to Motion re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. to Pltffs.' Stmn. of Disputed Facts (Redacted))(Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Arch. Intern. Med. 148:36-69 (1988).
Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part I, II Farmaco. 45(10):1043-1066 (1990).
Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part II, II Farmaco. 45(11):1137-1167 (1990).
Rice et al., Fluorine Probes for Investigating the Mechanism of Activation of Indeno[1,2,3-cd] Pyrene to a Tumorigenic Agent, Carcinogenesis 11(11):1971-1974 (1990).
Ridker et al., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of Rosuvastatin: a prospective study of the JUPITER trial, Lancet 373(9670):1175-82 (2009).
Ridker et al., Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New Eng. J. Med., 359(21):2195-2207 (2008).
Rietjens and Vervoort, Bioactivation of 4-Fluorinated Anilines to Benzoquinoneimines as Primary Reaction Products, Chem. Biol. Interact. 77(3):263-281 (1991).
Rifai et al., Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years, Clin. Chem. 50:10:1861-1870 (2004).
Roman et al., Renal Tubular Site of Action of Fluoride in Fischer 344 Rats, Anesthesiology 46(4):260-264 (1977).
Rosenblum et al., Discovery of 1-(4- Fluoropheny1)-(3R)43-(4-Fluorophenyl)-(3S)-Hydroxypropylk-(4S)-(4- Hydroxyphenyl)-2-Azetidinone (SCH 58235), A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, J. Med. Chem. 41(6):973-980 (1998).
Rosenblum et al., Discovery of SCH 58235, a potent orally active inhibitor of cholesterol absorption, XII International Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 61 (1995).
Roth et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase. I. Identification and Structure-Activity Relationships of a Novel Series of Fatty Acid Anilide Hypocholesterolemic Agents, J. Med. Chem. 35(9):1609-1617 (1992).
Salisbury et al., Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461, Atherosclerosis 115:45-63 (1995).
Salisbury, B. et al., 1995, "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" Atherosclerosis 115:45-63.
Sandberg and Slaunwhite, Differences in Metabolism of Prednisolone-C14 and Cortisol-C14, J. Clin. Endocrinol. Metab. 17(9):1040-1050 (1957).
Scandinavian Simvastatin Survival Study Group, Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S), Lancet 344(8934):1383-1389 (1994).
Schering Notice of Application for Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Oct. 17, 2008, Federal Court of Canada (Court File No. T-1610-08).
Schnitzer-Polokoff et al., Effects of Acyl-CoA:Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters, Comp. Biochem. Physiol. 99A:665-670 (1991).
Schnitzer-Polokoff, R. et al. 1991, "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma lipoprotein Composition in Hamsters" Comp. Biochem. Physiol. 99A:665-670.
Secrist et al., 2-Fluoroformycin and 2-Aminoformycin, Synthesis and Biological Activity, J. Med. Chem. 28(11):1740-1742 (1985).
Serway, Physics For Scientists & Engineers, Third Edition, (Updated Version), vol. 1, Saunders Golden Sunburst Series (Saunders College Publishing and Harcourt Brace College Publishers, Philadelphia), Table of Contents (1992).
Shankar et al., Synthesis of an Optically Pure 3-Unsubstituted β-Lactam Using an Asymmetric Reformatsky Reaction and its Conversion to Cholesterol Absorption Inhibitors, Tet. Lett. 37(24),4095-4098 (1996).
Shetty and Nelson, Chemical Aspects of Metoprolol Metabolism. Asymmetric Synthesis and Absolute Configuration of the 3-[4-(1-Hydroxy-2-methoxyethyl)phenoxy]-1-(isopropylamino)-2-propanols, the Diastereomeric Benzylic Hydroxylation Metabolites, J. Med. Chem. 31(1):55-59 (1988).
Silverman, Lead Modification: Drug Design and Development, in The Organic Chemistry of Drug Design and Drug Action, 2nd Ed., Sec. 2.2, pp. 29-32 (2004).
Simova, Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline, Chemical Abstracts 15:86 (1977) Abstract 106130h.
Simova, E. "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", Chemical Abstracts No. 15, vol. 86, Apr. 11, 1977, Abstract 106130h.
Sliskovic and White, Therapeutic Potential of ACAT Inhibitors as Lipid Lowering and Anti-Atherosclerotic Agents, Trends Pharmacol. Sci. 12:194-199 (1991).
Sommariva et al., Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia, Int. J. Clin. Pharmacol, Ther. Taxicol., 24(9):505-510 (1986).
Ståhle and Ljungdahl-Ståhle, Pharmacokinetics and Extracellular Distribution to Blood, Brain, and Muscle of Alovudine (3′-Fluorothymidine) and Zidovudine in the Rat Studied by Microdialysis, J. Acquir. Immune. Defic. Syndr. 6(5):435-439 (1993).
Stary et al., A Definition of Initial, Fatty Streak, and Intermediate Lesions of Atherosclerosis. A Report From the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Arterioscler. Thromb. Vasc. Biol. 14:840-856 (1994).
Statement for the Record in re Deposition of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).
Statement of Material Fact in Support re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07- cv-1334 (JLL/ES)).
Statement of Material Fact in Support re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Stedman's Medical Dictionary, www.medilexicon.comimedicaldictionary.php. Lippincott Williams & Wilkins (2006)—"prodrug".
Stein et al., Achieving Lipoprotein Goals in Patients at High Risk with Severe Hypercholesterolemia: Efficacy and Safety of Ezetimibe Co-administered with Atorvastatin. Am Heart J 2004; 148(3),447-55.
Stein et al., Lavastatis alone and in combination with resin in severe primary hypercholesterolemia, Arteriosclerosis 7:513A (1985).
Stein et al., Treatment of severe familial hypercholesterolemia with Lovastatin, resin and niacin, Arteriosclerosis 7:517A (1987).
Steinberg, An interpretive history of the cholesterol controversy: part 1, J. Lipid Res. 45:1583-1593 (1994).
Stipulation and Order dismissing action as to deft. Teva Pharmaceutical Industries, Ltd. Signed by Judge Jose L. Linares on Mar. 31, 2010. (nr) (Entered: Apr. 5, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Stipulation and Order terminating Deft. Mylan Inc., etc., Signed by Judge Jose L. Linares on Mar. 16, 2010. (dc, ) (Entered: Mar. 18, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Stipulation of Dismissal as to Defendant Mylan Inc. by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Letter)(Halper, Jason) (Entered: Mar. 11, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Stipulation of Dismissal as to Defendant Teva Pharmaceutical Industries Ltd. by MSP Singapore Company LLC, Schering Corporation. (Halper, Jason) (Entered: Mar. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).
Stipulation regarding Teva Pharmaceutical Industries Ltd. And Order, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).
Subcommittee on the National Halothane Study, "Summary of the National Halothane Study" J. Am. Med. Assoc. 197(10):121-134 (1966).
Summary Factfile, May 1992, "Anti-Atherosclerotic Agents" Current Drugs Ltd., pp. A5-A23.
Summary Factile, May 1992, "Anti-Antherosclerotic Agents" Current Drugs Ltd. pp. A5-A23.
Supplemental Expert Report of Ronald G. Brisbois, Ph.D., dated May 22, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Sybertz et al., SCH 48461, a novel inhibitor of cholesterol absorption, Atherosclerosis X, Workshop Abstracts, p. 89, Montreal, Oct. 10, 1994.
Sybertz, E. 1995, "SCH 48461, a novel inhibitor of cholesterol absorption" Atherosclerosis pp. 311-315.
Sybertz, E. J., et al., "SCH 48461, a novel inhibitor of cholesterol absorption,"Atherosclerosis X (proceedings of the 10th International Symposium on Atherosclerosis, Montreal, Quebec, Oct. 9-14, 1994), Pub. Elsevier; pp. 311-315, eds. Woodford, F.P. Davington, J. & Sniderman A. (cited as document C24 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341).
T. Durst et al., 1971, "Metallation of N-Substituted β-Lactams. A Method for the Introduction of 3-Substituents into β-Lactams" Canadian Journal of Chemistry, 50:3196-3201.
Tagg et al., Metabolic studies of tolbutamide in the rat, Biochemical Pharmacology 16(1):143-53 (1967).
Takahashi et al., Crystal structure of the covalent complex formed by a peptidyl-α-α-difluoro-β-keto amide with porcine pancreatic elastase at 1.78Å resolution, J. Am. Chem. Soc. 111:3368-3374 (1989).
Tanaka et al., 26,26,26,27,27,27-Hexafluoro-1,25-Dihydroxyvitarnin D3: A Highly Potent, Long-Lasting Analog of 1,25- Dihydroxyvitamin D3, Arch. Biochem. Biophys. 229(1):348-354 (1984).
Taylor et al., The metabolic fate of prazosin, Xenobiotica 7(6):357-64 (1977).
Taylor, Allen J. et al., Extended Release Niacin or Ezetimibe and Carotid Intima-Media Thickness, New Engl. J. Med. 361(22)2113-2122 (2009).
Teva Pharmaceuticals USA, Inc.'s Answer to Complaint (Attachments: Certification Pursuant to Local Civile Rule 11.2), dated Oct. 7, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).
Thornber, Isosterism and molecular modification in drug design, Chem. Soc. Review, 18(4),563-580 (1979).
Thummel et al., Human Liver Microsomal Enflurane Defluorination Catalyzed by Cytochrome P-450 2E1 Drug Metab. Dispos. 21:350-357 (1993).
Tidwell, Thomas T., Schiff Bases, and a Century of β-Lactam Synthesis, Angew. Chem. Int. Ed. 47:1016-1020 (2008).
Tingle et al., Influence of Glutathione Conjugation on the Immunogenicity of Dinitrophenyl Derivatives in the Rat, Int. Arch. Allergy Appl. Immunol. 91(2):160-165 (1990).
Tocco et al., Physiological Disposition and Metabolism of 5-(2′,4′ -Difluorophenyl)Salicyclic Acid, a New Salicylate, Drug Metab. Dispos. 3(6):453-466 (1975).
Topliss and Martin, Utilization of Operational Schemes for Analog Synthesis in Drug Design, in Drug Design (Ariens, ed.), ch. 1, pp. 1-21 (1975).
Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem. 15(10):1006-1011 (1972).
Transcript of Proceedings held on Aug. 12, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Transcript of Proceedings held on Sep. 15, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Transcript of Proceedings held on Sep. 8, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).
Trial Brief Defendants' (Filed Under Seal) by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA. (Attachments: # 1 Certificate of Service)(Lessler, Jay) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).
Trivedi et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N-[(1- Phenylcyclopentyl) Methyl]Ureas with Enhanced Hypocholesterolemic Activity, J. Med. Chem. 37(11):1652-1659 (1994).
Tsushima et al., Fluorine-Containing Amino Acids and Their Derivatives, 4. Synthesis and Antibacterial Activity of Threo and Erythro 1-Fluorodehydroxylated Chloramphenicol Analogues, J. Med. Chem. 28(2):253-256 (1985).
U.S. Appl. No. 07/995,488, filed Dec. 12, 1992, Davis.
U.S. Appl. No. 08/102,440, filed Sep. 21, 1993, Rosenblum.
USAN and the USP dictionary of drug names, U.S. Pharmacopeial Convention, Inc., entries ATEVI-ATRIM, p. 62 (though Jun. 15, 1993).
USP Dictionary of USAN and International Drug Names, U.S. Pharmacopeial Convention, Inc., entries AT-101-ATORV, p. 62 (though Jun. 15, 1994).
van Heek et al., Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, British J. Pharm, 129:1748-1754 (2000).
van Heek et al., Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats, British J. Pharm. 138:1459-1464 (2003).
van Heek et al., In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH4846I, J. Pharm. and Exp. Ther. 283(1):157-163 (1997).
van Heek et al., Isolation and identification of the active metabolite(s) of SCH48461 and possible in vivo mechanism of action for their inhibition of cholesterol absorption, XII Int'l Symp. ON Drugs Affecting Lipid Metabolism, Nov. 7. 1995, Houston, TX.
van Heek et al., The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys, Eur. J. Pharmacol. 415(1):79-84 (2001).
Velican and Velican, Coronary arteries in children up to the age of ten years, II. Intimal thickening and its role in atherosclerotic involvement, Med. Intern, 14:7-24 (1976).
Villines et al., The Arbiter 6-Halts Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration, J. Am. Coll. Cardiol. 55(24)1-6(2010).
Waters et al., Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients with Stable Coronary Disease in the TNT (Treating to New Targets) Study, J. Am Coll Card, 48(9)1793-1799 (2006).
Weeks et al., A Comparison of the Molecular Structures of Six Corticosteroids, J. Am. Chem. Soc. 95(9):2865-2868 (1973).
Weisweiler and Schwandt, Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia, Lancet 1212-1213 (Nov. 22, 1986).
Welch and Eswarakrishnan, Fluorine in Bioorganic Chemistry, John Wiley & Sons, NY, pp. 1-261 (1991).
Welch, Advances in the Preparation of Biologically Active Organofluorine Compounds, Tetrahedron 43(14):3123-3197 (1987).
Wermuth, Chemical modifications of medications with a view to the improvement of their action, Agressologie 7(3):213-219 (1966).
Wilhelm et al., 6-Fluoro-Vitamin D3: A New Antagonist of the Biological Actions of Vitamin D3 and its Metabolites which Interacts with the Intestinal Receptor for 1 α,25(OH)2-Vitamin D3, Arch. Biochem. Biophys. 233(1):127-132 (1984).
Williams, Drug Metabolism, in Principles of Medicinal Chemistry, Third Ed., Ch. 5, pp. 79-117 (Foye, ed.), Lea & Febinger, Philadelphia (1989).
Wirebaugh et al., A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin, Pharmacotherapy 12(6):445-450 (1992).
Witztum, Current Approaches to Drug Therapy for the Hypercholesterolemic Patient, Circulation 80:1101-1114 (1989).
Wolff et al., Substrate Specificity of Human Liver Cytochrome P-450 Debrisoquine 4-Hydroxylase Probed Using Immunochemical Inhibition and Chemical Modeling, Cancer Res. 45:2116-2122 (1985).
Wood et al., The Effect of Cimetidine on Anesthetic Metabolism and Toxicity, (1986) Anesth. Analg. 65(5):481488.
Woodrow, Essentials Of Pharmacology For Health Occupations, 4th Ed., Delmar, Thomson Learning, Ch. 7, pp. 87-139—"right amount" (2002).
Written Opinion dated May 16, 1995 in PCT/US94/10099.
Wu et al., A Novel One-Step Diastereo—and Enantioselective Formation of Trans-Azetidinones and its Application to the Total Synthesis of Cholesterol Absorption Inhibitors, J. Org. Chem. 64(10):3714-3718 (1999).
Yumibe et al., Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyoratadine by CYP3A4 and CYP2D6, Biochem. Pharm. 51:165-172 (1996).
Zia-Amirhosseini, Bioactivation by Glucuronide-Conjugate Formation, Adv. Pharma, 27:385-397 (1994).

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
WO2014093189A1 (en) 2012-12-10 2014-06-19 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date Type
USRE37721E1 (en) 2002-05-28 grant
DE122004000026I2 (en) 2005-09-29 grant
FI110321B (en) 2002-12-31 application
NL300132I1 (en) 2003-10-01 grant
DE10399001I2 (en) 2012-05-16 grant
NL300132I2 (en) 2003-11-03 grant
NL300172I1 (en) 2005-04-01 grant
NL300172I2 (en) 2005-08-01 grant
JP2803908B2 (en) 1998-09-24 grant
US5631365A (en) 1997-05-20 grant
LU91160I2 (en) 2005-11-25 grant
FI110321B1 (en) grant
CA2172149C (en) 2000-11-28 grant
DK0720599T3 (en) 1999-11-08 grant
RU2138480C1 (en) 1999-09-27 grant
DK720599T3 (en) grant
LU92544I2 (en) 2015-01-20 grant
DE69418613T2 (en) 1999-09-30 grant
EP0720599B1 (en) 1999-05-19 grant
ES2132432T3 (en) 1999-08-16 grant
LU91050A9 (en) application
KR186853B1 (en) 1999-05-01 grant
EP0720599A1 (en) 1996-07-10 application
FI961300A0 (en) 1996-03-21 application
LU91160A9 (en) application
DE122004000026I1 (en) 2004-11-18 grant
DE10399001I1 (en) 2003-06-12 grant
LU91050I2 (en) 2004-10-12 grant
DE69418613D1 (en) 1999-06-24 grant
FI961300A (en) 1996-03-21 application
LU92545I2 (en) 2015-09-21 grant
WO1995008532A1 (en) 1995-03-30 application
US5767115A (en) 1998-06-16 grant
CN1050830C (en) 2000-03-29 grant
FI961300D0 (en) grant
CN1131416A (en) 1996-09-18 application
JPH08509989A (en) 1996-10-22 application

Similar Documents

Publication Publication Date Title
US5354772A (en) Indole analogs of mevalonolactone and derivatives thereof
US4465632A (en) Process for preparing 1-6-and 2-substituted-1-carba-2-penem-3-carboxylic acids
US5561227A (en) Process for the stereospecific synthesis of azetidinones
US6093812A (en) Process for the stereospecific synthesis of azetidinones
US5229381A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
US6046214A (en) Heterocyclic compounds
US4260627A (en) 1-, 6- And 2-substituted-1-carba-2-penem-3-carboxylic acids
US20040162323A1 (en) Prostaglandin D2 antagonist
US4206219A (en) 6- and 1-Substituted-1-carbadethiapen-2-em-3-carboxylic acid
WO2005021497A2 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
EP0179559A2 (en) Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
WO1994014434A1 (en) Endothelin receptor antagonists
EP0289380A1 (en) Aryl-heteroaryl-carbinol derivatives having an analgesic activity
WO2005047248A1 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2001064632A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
US5688787A (en) Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US20050267049A1 (en) Anti-hypercholesterolemic compounds
WO1997016455A1 (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
JP2001354563A (en) Medicine comprising substituted benzylamines
US5013749A (en) Imidazole derivatives and their use as hypercholesterolemia and hyperlipoproteinemia agents
WO2005044256A1 (en) 2-azetidinones as anti-hypercholesterolemic agents
WO2001064634A1 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
WO2001064633A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
US20070078098A1 (en) Anti-hypercholesterolemic compounds
US5756470A (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHERING CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSENBLUM, STUART B.;DUGAR, SUNDEEP;BURNETT, DUANE A.;AND OTHERS;REEL/FRAME:028974/0188

Effective date: 19940803

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028974/0213

Effective date: 20120502